

Prof Reuven Zimlichman
Chief of Medicine and Hypertension Institute, The E. Wolfson Medical Center
P.O.B. 5, Holon 58100 Israel and
Head of Cardiovascular Research Institute,
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
Phone: 972-3-5028614, FAX: 972-3- 5032693
e-mail: zimlich@post.tau.ac.il

April 24, 2016

Motivation letter

To:

The Nominating Committee, the Council of Hypertension

Application for nomination as a member of The Council of Hypertension

To All Concerned:

I, forward this letter of intent to express my sincere interest in the position of member of the Council of Hypertension.

I will do my best to contribute to the activities of the working group in scientific areas, in teaching young physicians and organizing science exchange between members of the group, of the ESC and other physicians.

I believe that we should enhance the involvement of the ESC members, National Societies and others to share and spread knowledge, to engage young physicians in research and aim to improve their skills in treatment of patients, in performing research and cooperation between countries and excellence centers.

Sincerely yours

Reuven Zimlichman

Prof R. Zimlichman FAHA, FASH, FESC, FESH
Chief Dept. of Medicine and Hypertension Institute and
Director of the Brunner Institute for Cardiovascular Research
Sackler Faculty of Medicine, Tel-Aviv University
The E. Wolfson Medical Center
Director of the Institute for Quality in Medicine
Israeli Medical Association.
P.O.B. 5, Holon 58100 Israel.
phone: 972-3-5028614, FAX: 972-3- 5032693
e-mail: zimlich@post.tau.ac.il

Short description :

July 2015

Prof. Reuven Zimlichman

Chief of Medicine and Hypertension Institute, The E. Wolfson Medical Center

P.O.B. 5, Holon 58100 Israel and

Head of Cardiovascular Research Institute,

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

Phone: 972-3-5028614, FAX: 972-3- 5032693

email: zimlich@post.tau.ac.il

Prof. R. Zimlichman, M.D. is presently Chief Departments of Medicine and Head of Hypertension Institute at the E. Wolfson Medical Center, Israel; he is the Director of The Brunner Cardiovascular Research Institute, Tel-Aviv University. He is also the immediate past Vice Dean and Head of School of Continuing Education, Sackler Faculty of Medicine, Tel Aviv University.

Prof. Zimlichman did his fellowship in Hypertension at the Hypertension Endocrine Branch, NIH, NHLBI in Bethesda, Maryland, USA (1983 to 1986). During the following years he returned for prolonged periods of research in the Hypertension Endocrine Branch and in the Clinical Neurocardiology section.

Prof. Zimlichman joined the Faculty of Health Sciences at Ben Gurion University and Soroka Medical Center in Beer Sheva, Israel. He was nominated as Chief of Clinical and Experimental Hypertension in the Faculty of Medicine and in the Medical Center.

Prof. Zimlichman was nominated as Chief of Medicine in the Sheba Medical Center, Tel Hashomer, in 1989 and was nominated as Associate Professor in Medicine at the Tel Aviv University, Sackler School of Medicine in 1994. In 1991 Prof Zimlichman was nominated as Chief of Department of Medicine in the Wolfson Medical Center, and in 1998 was nominated as Chief Departments of Medicine at the Wolfson Medical Center. In 2008 he was nominated as Full Professor of Medicine in Internal Medicine in Tel Aviv University.

Prof Zimlichman was nominated as Head of University Institute of Cardiovascular Research, Tel Aviv University and Wolfson Medical Center.

He is currently a member of the board of directors, The Israeli Society for prevention of Acute Myocardial Infarction, Ministry of Health. Member, Steering Committee, the Israeli Study of Congestive Heart Failure.

Prof Zimlichman acted for years as the Chairman of the Supreme Court, Israeli Medical Association, and at present continues to act as a member of this Supreme Court.

Prof Zimlichman acted also as the President of the Israeli Society of Hypertension.

Since 2015, Prof Zimlichman acts as the Director of the Institute for Quality in Medicine, Israeli Medical Association.

Prof. Zimlichman published more than 200 original research scientific publications, 5 books and multiple chapters in books. His publications are in basic research, cell cultures, animal research and clinical research. The majority of his publications are in the field of hypertension, cardiovascular disease, metabolic syndrome, end organ damage and evaluation of arterial properties.

Reuven Zimlichman M.D.

CURRICULUM VITAE

Identity No: 60592334

Date and place of birth: March 16, 1948, Warsaw, Poland.

Place of work: E. Wolfson Medical Center, 62 Halohamim St. Tel Giborim, Holon
58100, Israel.

Department: Chairman of Medicine, Head, Department of Internal Medicine
and Hypertension. Director, The Brunner Institute for Cardiovascular Research, Wolfson
Medical Center and Tel Aviv University.

Vice Dean School of Medicine.

Office phone: 972-3-5028614, email: Zimlich@post.tau.ac.il

Home address: 53 David Hamelech Str. Herzlia, 46661 Home phone: 972-9-9571157

Marital status: Divorced, 6 children

Military service: October 1973 - October 1977 (Leut. Colonel)

A. Education

<u>Period of Study</u>	<u>Name of University</u>	<u>Subject</u>	<u>Degree</u>	<u>Awarded</u>
1966-1972	Hebrew University, Jerusalem	Medicine	M.D. Lic. #11334	1974
1969-1971	Hebrew University	Research work Clinical Endocrinology		

Title of Doctoral Dissertation:

"Renin Response to Furosemide and Hypertonic Saline Infusion, A Convenient Test for Release and Inhibition of Renin"

Supervisor: Prof. D. Rabin

1972-1975	Soroka Medical Center	Specialist in Medicine	Lic. # 7432,	1972
-----------	-----------------------	---------------------------	--------------	------

B. Further Studies

<u>Period of Study</u>	<u>Name of Institution</u>	<u>Subject</u>	<u>Degree Awarded</u>
1983-1985	NIH, NHLBI Bethesda, MD, USA	Hypertension Clinical and Research	Fellowship in Hypertension
1986	NIH, NHLBI Bethesda, MD, USA	Hypertension Clinical and Research	Fellow in Hypertension

1987	NIH, NHLBI Bethesda, MD, USA	Hypertension Clinical and Research	Fellow in Hypertension
2002	NIH, NHLBI Bethesda, MD, USA	Section of Neurocardiology	Fellow in Hypertension

C. Academic Experience

<u>Period</u>	<u>Name of Institution</u>	<u>Department</u>	<u>Rank/Function</u>
1978-1982	Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva	Medicine	Instructor in Medicine
1982-1985	Faculty of Health Sciences, Ben Gurion University, Beer Sheva	Medicine	Lecturer in Medicine
1985-1989	Faculty of Health Sciences, Ben Gurion University, Beer Sheva	Medicine	Senior Lecturer in Medicine
1985-1989	Faculty of Health Sciences, Ben Gurion University, Beer Sheva		Head, Hypertension Research
1992-1994	Tel Aviv University Sackler School of Medicine		Senior Lecturer in Medicine
1994-present	Tel Aviv University Sackler School of Medicine		Associate Professor in Medicine
1995- present	Chairman of Search and Nominations Committee Wolfson Medical Center, Israel		
1995- present	Member of the Senate, Tel Aviv University		
1996 - present	Chairman, Supervising Committee of Teaching in Internal Medicine in Tel Aviv University [affiliated] Hospitals		
1998-present	Director, The Brunner Institute for Cardiovascular Research, Tel Aviv University and Wolfson Medical Center		
1998-present	Member, Israeli Board Certification Committee, Israeli Medical Association.		

1998-2002 Member of the Teacher- Student Committee, School of Medicine, Tel Aviv University

1998-2003 Member of Research Committee, School of Medicine, Tel Aviv University

2002-2006 Chairman, Supervising Committee of Teaching in Internal Medicine in Tel Aviv University (affiliated) Hospitals.

1998-2004 Member of Nominations Committee, School of Medicine, Tel Aviv University

1998-2004 Member of Education and Peer Evaluation Committee, School of Medicine, Tel Aviv University

1998-2006 Member of Teaching Coordination Committee, School of Medicine, Tel Aviv University

2000-present Member of the Board of Directors, The Israeli Society for Prevention of Acute Myocardial Infarctions, Ministry of Health

2001-2008 Chairman of the Supreme Court, Israeli Medical Association

2001-2008 Member, Steering Committee, The Israeli Study of Hospitalized Patients with CHF, by the Israeli Society of Internal Medicine and The Israeli Society of Cardiology.

2003-2014 Member, Board of Directors, Mediterranean Society of Cardiology and Cardiovascular Surgery.

2005-2014 Superintendent of the Professions of Internal Medicine, Israeli Medical Association.

2005-2008 President, Israeli Society of Hypertension

2006-2014 Vice Dean, Sackler School of Medicine, Tel Aviv University.

2006-2014 Head, School of Continuing Education, Sackler School of Medicine, Tel Aviv University

C1. Clinical Experience

<u>Period</u>	<u>Name of Institution</u>	<u>Department</u>	<u>Rank/Function</u>
1972-1973	Hadassah Hospital, Jerusalem	Medicine	Internship
1977-1982	Soroka Medical Center, Beer Sheva	Medicine	Residency
1982	Specialist in Internal Medicine Israeli Board Certificate No. 7432		
1982-1983	Soroka Medical Center, Beer Sheva	Medicine	Attending Physician
1983-1985	NIH, NHLBI, Bethesda, MD, USA		Attending Physician Clinical and Research
1986 (3 months)	Same as above		

1987 (3 months)	Same as above	
1985-1989	Soroka Medical Center, Beer Sheva	Attending Physician
1985-1989	Soroka Medical Center, Beer Sheva	Head of Hypertension Services
1989-1991	Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan	Chief of Medicine
1991-present	The E. Wolfson Medical Center	Chief of Medicine and Hypertension Institute
3/2002-7/2002	NIH, NINDS, Bethesda, MD, USA Sabbatical	Research Project

D. Active Participation in Scientific Meetings

<u>Year</u>	<u>Name of Meeting</u>
1982	The Annual Meeting of the Israeli Society of Physiology and Pharmacology, Bar Ilan University, Ramat Gan (two presentations)
1982	The Annual Meeting of the Israeli Society of Physiology and Pharmacology, Weizmann Institute of Science, Rehovot (one presentation)
1983	The Biannual Meeting of the Israeli Society of Medicine. Tel Aviv (two presentations)
1984	The 39th Annual Fall Conference of the Council for High Blood Pressure Research, Cleveland, Ohio
1985	The Annual Meeting of the American Society for Clinical Investigation, Washington D.C. (two presentations)
1985	The Annual Meeting of the American Federation for Clinical Research, Washington D.C. (one presentation)
1985	The Annual Meeting of the American Society of Bone and Mineral Research, Washington D.C. (one presentation)
1985	The Israeli Society of Medicine Meeting, Shefaiim
1985	The 40th Annual Fall Conference of the Council for High Blood Pressure Research. Cleveland, Ohio (two presentations)
1985	The 2nd International Symposium on Hypertension in the Community, Jerusalem, Israel (two presentations)
1986	The American Federation for Clinical Research Meeting, Washington D.C. (two presentations)
1986	The International Society of Hypertension Meeting, Essen, FRG.
1986	The 11th Scientific Meeting of the International Society of Hypertension, Heidelberg, FRG

- 1987 Cell Calcium Metabolism, VIIth International Washington Spring Symposium, Washington
- 1988 The 12th Scientific Meeting of the International Society of Hypertension, Kyoto, Japan
- 1988 Calcium Antagonists in Cardiovascular Disease, Satellite of the 12th Scientific Meeting of ISH, Nagoya, Japan
- 1988 The 12th World Congress of the Israeli Medical Association, Jerusalem
- 1989 Israel- Germany Binational Meeting, Eilat, Israel
- 1989 The Annual Meeting of the Israeli Heart Society. Tel Aviv, (two presentations)
- 1989 Calcium in Cardiovascular Disease, an International Symposium, Eilat, Israel (five presentations)
- 1989 Fourth European Meeting on Hypertension, Milan (two presentations)
- 1989 Proceedings of the Israeli Society of Hypertension, Medax.
- 1990 The Fifth Scientific Meeting of The American Society of Hypertension, New York (three presentations)
- 1991 The Annual Meeting of The Israeli Society of Endocrinology (one presentation).
- 1991 The Sixth Scientific Meeting of The American Society of Hypertension, New York (one presentation)
- 1992 The 13th Meeting of the International Society of Hypertension, Madrid, Spain.
- 1992 The Seventh Scientific Meeting of the American Society of Hypertension, New York
- 1994 The 14th Meeting of the International Society of Hypertension, Melbourne, Australia.
- 1994 The Eighth Scientific Meeting of The American Society of Hypertension, New York
- 1994 9th European Congress of Anesthesiology, Jerusalem. Invited state of the art review- "Perioperative management of the hypertensive patient".
- 1995 The Ninth Scientific Meeting of The American Society of Hypertension, New York, May 17-21 (six presentations)
- 1995 The Annual Meeting of the Israeli Society of Nephrology and Hypertension, Zichron Yaacov, Israel, June 1-2 (two presentations)
- 1995 The European Society of Hypertension Meeting, Milan Italy, June 8-12, 1995
- 1995 IEN Meeting on Peak and Trough in Hypertension Treatment, Geneva, June 22-25, (one presentation)

- 1995 European Meeting on Calcium Antagonists. Amsterdam, Oct 25-28
- 1996 Annual Meeting of the Israeli Heart Society, Hilton, Tel Aviv, (one presentation). April, 1996
- 1996 The Ninth Scientific Meeting of The American Society of Hypertension, New York, May
- 1996 The 15th Meeting of the International Society of Hypertension, Glasgow, Scotland
- 1996 The 18th Congress of the European Society of Cardiology, August, Birmingham, England
- 1996 International Geriatric Conference on Aging in the Mediterranean & the Middle East, Tel Aviv, September. Invited state of the art review- "Treatment of hypertension in the elderly"
- 1996 9th Annual Meeting of The Mediterranean Association of Cardiology and Cardiac Surgery, Tel Aviv, October 1996.
- 1996 Angiotensin II Antagonism in Hypertension, Frankfurt, Germany, October 1996.
- 1997 The Tenth Scientific Meeting of The American Society of Hypertension, New York, May, 1997.
- 1997 The European Society of Hypertension Meeting, Milan, Italy, June 1997.
- 1999 The 3rd International Symposium on Angiotensin II Antagonism, Monte Carlo.
- 1999 32nd Annual Meeting of the American Society of Nephrology (ASN), USA.
- 1999 Renal Week (American Society of Nephrology), Miami, Florida.
- 2000 12th International Symposium on Atherosclerosis, Stockholm, Sweden.
- 2001 The 7th annual meeting of the Society for Research, Prevention and Treatment of Atherosclerosis, Israel.
- 2001 The 4th Annual Meeting of the Israeli Society of Hypertension, Israel.
- 2001 The 3rd International Symposium on Perioperative Cardiac Care: A joint Anesthesiology- Cardiology meeting, Tel Aviv, February 2001.
- 2003 The American Society of Hypertension Meeting, May, New York.
- 2003 18th International Diabetes Federation Congress, 24-29 Aug. 2003, Paris, France
- 2003 5th International Congress on Coronary Artery Disease, Florence, Italy, October
- 2004 The European Society of Hypertension, Paris, June 2004.
- 2005 1st International congress on "Prediabetes" and the Metabolic syndrome, April, Berlin, Germany.
- 2005 15th European meeting on Hypertension, Milan, Italy, June 2005.

- 2005 European Society Cardiology Meeting (ESC) Stockholm, Sweden, August 2005.
- 2005 5th International Meeting on Coronary Artery Disease, Paris France, September 2005
- 2005 6th International Congress on Coronary Artery Disease, Istanbul, Turkey, October 2005.
- 2006 American Hypertension Meeting, New York USA, August 2006
- 2006 European Hypertension Meeting, Madrid, June 2006

Listing stopped due to numerous presentations.

E. Academic and Professional Awards

<u>Year</u>	<u>Name of Institution</u>	<u>Award</u>
<u>1. Prizes:</u>		
1972	Hadassah Medical School	Best Student Medical School
1983	Ben Gurion University, <i>Faculty of Health Sciences</i>	The "Tabb" award for outstanding research work
<u>2. Fellowships</u>		
1983-1985	Hypertension Endocrine Branch, NIH, NHLBI, Bethesda, MD	Fogarty Fellowship Visiting Associate
Feb-Apr 1986	Hypertension Endocrine Branch, NIH, NHLBI, Bethesda, MD	Fogarty Fellowship Visiting Associate
Sept-Dec 1987	Hypertension Endocrine Branch, NIH, NHLBI. Bethesda, MD	Fogarty fellowship Visiting Associate
March-August 2002	Clinical Neurocardiology Section NIH, NCI. Bethesda, MD	Sabbatical.
<u>3. Grants</u>		
1982-1983	The Bat Sheva de Rothschild Research Grant "Cytosolic calcium levels in cells from hypertensive and normotensive rats"	
1986-1989	Bayer Research Grant "Hemodynamic effects of nisoldipine in hypertensive patients"	

- 1987-1989 Chief Scientist Award- Research- Israeli Ministry of Health
"Catecholamine levels in hypertensive rats"
- 1993-1995 Chief Scientist Award- Research- Israeli Ministry of Health.
"Effect of growth factors on left ventricular hypertrophy in cultured cardiomyocytes".
- 1994-1995 Bayer Basic Research Grant
"Effect of atrial natriuretic peptide on left ventricular hypertrophy in cultured cardiomyocytes of SHR and WKY rats"
- 1996-1998 Chief Scientist Award- Research- Israeli Ministry of Health
"Gene cloning in mucopolidosis IV" (with Dr. E. Goldin)
- 1998-2000 MSD Basic Research Grant
"Evaluation of arterial compliance in hypertensive patients".
- 1999-2001 Novartis Research Grant
"Effect of antihypertensive treatment on arterial compliance in hypertensive patients"
- 2001-2003 " Arterial elasticity and glucose metabolism and insulin resistance"
Research grant sponsored by Glaxo Smith Klein.
- 2004-2006 "Arterial properties and optimalization of glucose levels- is it possible to minimize cardiovascular events by lowering glucose to normal levels"
Research grant sponsored by Aventis.

F. Membership In Professional Societies

<u>Year joined</u>	<u>Society</u>
1977	Israeli Medical Association
1982	Israeli Society of Internal Medicine
1982	Israeli Society for Clinical Investigation
1985	Israeli Society of Hypertension
1983	American Association for the Advancement of Science
1983	The Council for High Blood Pressure Research, USA 1996 Nomination as an International Fellow
1985	International Society of Hypertension.
1987	European Society of Clinical Investigation
1988	American Society of Hypertension
1989	The European Society of Hypertension
1989	The Israeli Society of Nephrology and Hypertension
1989	The Israeli Society of Atherosclerosis
1995	Israeli Medical Association - Scientific Council - Council of Internal Medicine.
1995	Israeli Medical Association- Scientific Council - Educational Council
1995	Israeli Society of Cardiology
1996	Israeli Medical Association- Scientific Council - Member of the Board Examinations in Medicine
2001	The European Society of Cardiology
2001	Member of the Working Group on Hypertension and the Heart, ESC
2002	Member of the Working Group (Organizing Committee) on Peripheral Circulation, ESC.

G.1. MD Students Supervised by Candidate

<u>Year</u>	<u>Name of Student</u>	<u>Subject of Thesis</u>	<u>Institution</u>
1. 1988-9	D. Mossinson	“Assessment of the hemodynamic changes in the early phase of acute	Ben Gurion University of the Negev

myocardial infarction”

2.	1989-90	D. Leibovitz	Effects of acute alcohol load on myocardial performance and hemo-dynamic parameters in normal volunteers”	Ben Gurion University of the Negev
3.	1990-91	O. Brautbar	“Longitudinal follow up of blood pressure in Dead Sea workers, possible effect of low altitude”	Ben Gurion University of the Negev
4.	1991-92	M. Tan	“Isometric effort test in the evaluation of essential hypertension”	Ben Gurion University of the Negev
5.	1994-95	B. Aman	“The acute hemodynamic effects of smoking in healthy volunteers”	Tel Aviv University
6.	2002-03	D. Peres	“The hemodynamic effects of smoking in healthy volunteers: evaluation of arterial compliance”	Tel Aviv University

G2. M.Sc Students Supervised by Candidate

<u>Year</u>	<u>Name of Student</u>	<u>Title of Project</u>	<u>Name of Hospital</u>	
1.	1995-98	I. Arez	Effects of weight loss on hemodynamic parameters in untreated hypertensive patients	Wolfson Medical Center
2.	1995-98	E. Melamed	Acarbose and Blood Pressure effects in Sucrose Induced Hypertension in Rats.	Wolfson Medical Center
3.	2001-02	H. Gutman	The effects of L-arginine on arterial compliance: evaluation of the effects of prolonged treatment	Wolfson Medical Center

4.	2003-05	M. Cimand	Effect of Homocysteine lowering therapy with folic acid, vitamin B12 and vitamin B6 on vascular compliance and growth factors in patients with high risk of cardiovascular disease.	Wolfson Medical Center
5.	2002-05	N. Garti	Malnutrition, inflammation and atherosclerosis (MIA syndrome) in hemodialysis patients cross-sectional study in Israel.	Wolfson Medical Center
6.	2004-07	K. Confino	Cardiovascular effect of Aldosterone blockade with Spironolactone in patients with high risk of cardiovascular disease.	Wolfson Medical Center
7.	2004-05	O. Debi	Effect of antioxidants vitamin C, vitamin E, Q-10 and selenium on vascular compliance and growth factors in patients with high risk of cardiovascular disease.	Tel Aviv University
8.	2007-2009	S. Pasternak	The correlation between anatomic-physiologic cardiac status and arterial elasticity in hypertensive patients.	Tel Aviv University
10.	2010- 2014	B. Helman	The correlation between Lp-PLA2 and recurrent coronary events in patients with CHD. The BIP study cohort).	Tel Aviv University.
11.	2012-2014	E. Biron	The effect of Hemodialysis on arterial properties. Comparison of Arteriovenous fistula and direct vascular access.	Tel Aviv University and Wolfson Medical Center.

G3. Ph.D Students supervised by candidate:

2005	L. Rosen	Metabolic and hemodynamic aspects of Rimonabant, in process of approval.	Wolfson Medical Center
------	----------	--	------------------------

G.4. Residents' Basic Science Projects Supervised by Candidate

	<u>Year</u>	<u>Name of Resident</u>	<u>Title of Project</u>	<u>Name of Hospital</u>
1.	1985	D. Zilberman	Hemodynamic effects of a novel calcium channel blocker-Nisoldipine in hypertension	Soroka Medical Center
2.	1986	B. Menzelevski	Evaluation of hemodynamic parameters of nisoldipine in elderly hypertensive patients	Soroka Medical Center
3.	1987	V. Gueta	Non-invasive evaluation.of cardiac parameters for optimal pacemaker setting	Soroka Medical Center
4.	1988	L. Eidelman	Evaluation of hemodynamic parameters during treatment of hypertension with enalapril	Soroka Medical Center
5.	1989	N. Gasper	Hemodynamic effects of captopril in young hypertensive patients	Soroka Medical Center
6.	1994	N. Debi	Detection of intrauterine growth retardation in hypertensive pregnancies	Wolfson Medical Center
7.	1994	R. Tobar	Hemodynamic effects of felodipine in hypertensive patients	Wolfson Medical Center
8.	1995	A. Sagiv	Effects of oophorectomy on hemodynamic parameters	Wolfson Medical Center
9.	1995	B. Rosen	The effects of vasoactive substances on cytosolic calcium and proliferation rate of vascular smooth muscle cells from SHR and WKY aortas	Wolfson Medical Center
10.	1995	A. Shkedi	The effect of hyperinsulinemia on vascular damage in the kidney	Wolfson Medical Center

11.	1996	M.Shargorodsky	Hemodynamic effects of the cold pressor test in the diagnosis of hypertension	Wolfson Medical Center
12.	1997	H. Steiner	Evaluation of cardiovascular risk in a cohort of post MI patients	Wolfson Medical Center
13.	1998	N. Timkin	Effect of antihypertensive treatment with losartan on arterial compliance	Wolfson Medical Center
14.	1998	L. Lubimov	Effect of treatment with Diovan on arterial compliance	Wolfson Medical Center
15.	2002-3	Dr. I. Davidovitz	Effects of treatment with low dose HCTZ on arterial elasticity and metabolic parameters	Wolfson Medical Center
16.	2002-3	Dr. Z. Halfin	Effects of mental stress on hemodynamic parameters and arterial elasticity	Wolfson Medical Center
17.	2002-3	Dr. A. Flid	Evaluation of arterial elasticity after significant weight loss in morbid obesity	Wolfson Medical Center
18.	2003-5	Dr. R. Dudaie	Arterial elasticity in patients with end organ damage	Wolfson Medical Center
19.	2003-4	Dr. N. Hazanov	Effects of statins on arterial elasticity in patients with familial hypercholesterolemia	Wolfson Medical Center
20.	2003-4	Dr.M. Beniashvili	Effects of the combination of statins and calcium channel blockers on arterial properties in diabetic-hypertensive patients	Wolfson Medical Center
21.	2003-4	Dr. K.Michaelova	Effects of improving insulin receptor sensitivity on small and large artery compliance	Wolfson Medical Center
22.	2003-4	Dr. M. Peer	Correlation between left ventricular mass and arterial elasticity in hypertensive patients with and without LVH.	Wolfson Medical Center
23.	2004-5	Dr. M. Shur	The correlation between arterial compliance and haptoglobin genotype in patients with diabetes mellitus.	Wolfson Medical Center
24.	2004-5	Dr. Einat As	Comparison of conventional dose (16 mg) with high dose (32 mg) of Candesartan on arterial elasticity in patients with arterial hypertension.	Wolfson Medical Center

25.	2005-	Dr. N. Wasiuli	Inter-arm blood pressure difference: effect on arterial properties. A study of arterial elasticity in both arms.	Wolfson Medical Center
26.	2004-	Dr. S. Matzkin	The Correlation between arterial elasticity and endothelial function: A study of patients with CVRF.	Wolfson Medical Center
27.	2005-	Dr. E. Lukitz	Determination of the correlation between osteoporosis and arterial stiffness.	Wolfson Medical Center
28.	2014-	J. Ben Aharon	The effect of Hemodialysis on endothelial function.	Wolfson Medical Center.

Participation in Professional Journals:

Membership, editorial board Scientific Journals:

1. Member, Editorial board, Israel Medical Association Journal (IMAJ).
2. Member, Editorial board Israeli Bilingual Journal of Hypertension, Screening, Investigation, Therapy.
3. Member, Editorial board, Israeli Journal of Military Medicine (JIMM).
4. Member, Editorial Board, Faculty Journal of Tel-Aviv University, Sackler Faculty of Medicine.
5. Chairman Editorial Board, Journal of Internal Medicine, Aurora group.
6. Member, Editorial Board of The Cardiometabolic Syndrome Journal (JCMS).
7. Member, Editorial Board, Journal of the American Society of Hypertension (JASH).
8. Member, Editorial Board, Journal of Cardioresnal Medicine.
9. Journal of Cardiac Failure.
10. Journal of Cardiometabolic Syndrome.

Ad Hoc Reviewer:

1. American Journal of Hypertension.
2. Hypertension.
3. Israeli Medical Association Journal.
4. Harefuah.
5. Hypertension (Medical Media, Israel).
6. Annals of Internal Medicine.
7. Journal of Cardiometabolic Syndrome.
8. American Journal of Cardiology.
9. Journal of Cardiac Failure.
10. Molecular Nutrition and Food Research.
11. J of Cardiovascular Diabetology.
12. Clinical Biochemistry.
13. Journal of Hypertension.

14. Journal of Israeli Military Medicine.
15. Journal of Cardiorenal Medicine.
16. Molecular Nutrition & food Research.
17. Nutrition and Metabolism.
18. Molecular Nutrition and Food Research
19. Journal of the Renin-Angiotensin-Aldosterone System.
20. Israel Medical Association Journal (IMAJ).
21. Molecular Nutrition and Food Metabolism.
22. African Journal of Biotechnology.
23. Experimental Lung Research.
24. Hormone and Metabolism Research.
25. Journal of American Heart Association.
26. Journal of American Society of Hypertension.
27. Journal of Israeli Military Medicine.
28. Journal of Human Hypertension.

Meeting Organization (Member of organizing committee):

1. Trends in Modern Treatment of Hypertension, As satellite of the Mediterranean Congress of Cardiology and Cardiovascular Surgery, 1995, Tel Aviv.
2. Hypertension in the elderly, Hadassah Medical Organization meeting. Jerusalem 1998.
3. 7th International Symposium on Hypertension in the Community: Screening, Investigation and Therapy. Limasol, Cyprus, December 2000- Member of International Advisory Board.
4. The 5th International Congress on Coronary Artery Disease – From Prevention to Intervention – ICCAD – Florence, Italy, October 2003.
5. The 3rd International Symposium on Perioperative Cardiac Care: A joint Anesthesiology- Cardiology Meeting, Tel Aviv, February 2001. Member, Executive committee, XVI Annual Meeting of Mediterranean Association of Cardiology and Cardiac Surgery. In Collaboration with the ESC working group on Cardiovascular surgery & the ESC Working Group on Valvular Heart Disease, Bodrum, Turkey, September 2004.
6. 1st International Congress on “Prediabetes” and the Metabolic Syndrome – Berlin, April, 2005.

7. ICADD, The 6th International Congress on Coronary Artery Disease, Istanbul, Turkey, Nov. 2005.
8. ICADD, The 7th International Congress on Coronary Artery Disease, Nov. 2007.
9. The 1st International Congress of PreHypertension and Cardiovascular Risk, April 2008, Prague.
10. International Conference on Fixed Combination in the Treatment of Hypertension and Dyslipidemia, Intercontinental Hotel, Budapest, Hungary, 7-10 February, 2008.
11. International Conference on PreHypertension & CardioMetabolic Syndrome, February 24-27, 2011. Vienna, Austria. Conference chairman.

Member, Board of Directors

1. Member, board of directors, Israeli Association for prevention of heart attacks. Ministry of Health.
2. Member, Nomination Committee Health Professions , Tel Aviv University, 10.2002-10.2004
3. Member, Working Group on Hypertension and the Heart, European Society of Cardiology, November, 2003.
4. Member, Working Group on Peripheral Circulation, European Society of Cardiology, November, 2003.
5. Member Board of Directors Mediterranean Association of Cardiology and Cardiac Surgery.
6. Chairman, The Supreme Court, Israeli Medical Association, 2003.
7. Superintendant of Professions of Internal Medicine, Israeli Medical Association, 2005 – present.
8. The Israeli Association for Cardiovascular Trials, Member of the board.
9. Member of the board of Artery Society.

A. BOOKS WRITTEN

1. **R. Zimlichman**, Y Shoenfeld. Hypertension prevention and treatment. Yediot Ahronot Press, 339 pp. 1991.
 - 1a. **R. Zimlichman**, Y Shoenfeld. Hypertension prevention and treatment. Yediot Ahronot Press, 339 pp. 1994. Second edition.
-
2. **R. Zimlichman**. Hypertension, therapeutic approach
Prolog Press, 1998.
 3. **R. Zimlichman**. The Metabolic Syndrome, 1999.
 4. **R. Zimlichman** – Y. Shoenfeld – Hypertension guide to medical treatment. Prolog Press, 2000.

B-1. ORIGINAL ARTICLES

1. **R. Zimlichman**, A. Rosler, D. Rabin.
Renin response to furosemide and hypertonic saline infusion, a convenient test for release and inhibition of renin.
Isr J Med Sci, Vol. 10, pp. 1562-1567, 1974.
2. R. Levy, **R. Zimlichman**, A. Keynan, A. Livne.
The erythrocyte membrane in essential hypertension-modified temperature dependence on lithium efflux.
Biochem Biophys Acta, Vol. 685, pp. 214-218, 1982.
3. **R. Zimlichman**, C. Chaimovitz, Y. Chaitchenko, M. Goligorsky, J. Rapaport, J. Kaplanski.
Vascular hypersensitivity to noradrenaline: a possible mechanism of hypertension in rats with chronic uremia.
Clin Sci, Vol. 67, pp. 161-166, 1984.
- 4a. D.S. Goldstein, R.W. Stull, **R. Zimlichman**, P.D. Levinson, H. Smith, Keiser H.R.
Simultaneous measurement of DOPA, DOPAC, and catecholamines in plasma, by liquid chromatography with electrochemical detection.
Clin Chem, Vol. 30, pp. 815-816, 1984.
- 4b. D.S. Goldstein, R.W. Stull, **R. Zimlichman**, P.D. Levinson, H. Smith, H.R. Keiser.
Simultaneous measurement of DOPA, DOPAC, and catecholamines in plasma, by liquid chromatography with electrochemical detection.
Electrochemical Detections and Separations, Vol. 2, pp. 1-3, 1986.
5. D.S. Goldstein, P.D. Levinson, **R. Zimlichman**, A. Pitterman, R.W. Stull, H.R. Keiser.
Clonidine suppression testing in essential hypertension.
Ann Int Med, Vol. 102, pp. 42-49, 1985.

6. D.S. Goldstein, **R. Zimlichman**, R.W. Stull, J. Folio, P.D. Levinson, H.R. Keiser, I.J. Kopin. Measurement of regional neuronal removal of epinephrine in man, *J Clin Invest*, Vol. 76, pp. 15-21, 1985.
7. D.S. Goldstein, R.F. Bonner, **R. Zimlichman**, T.P. Zahn, R.O.III Cannon, D.R. Rowsing, R.W. Stull, H.R. Keiser. Indices of sympathetic vascular innervation in sympathectomized patients. *J Auton Nerv Sys*, Vol. 15, pp. 309-318, 1986.
8. R. Udelsman, J.P. Harwood, M.A. Millan, G.P. Chrousos, D.S. Goldstein, **R. Zimlichman**, K.J. Catt, G. Aguilera. Functional receptors for corticotropin releasing factor in the primate peripheral venous system. *Nature*, Vol 319, pp. 147-150, 1986.
9. **R. Zimlichman**, S. Zimlichman, D.S. Goldstein, H.R. Keiser. Intracellular free calcium in platelets of spontaneously hypertensive rats. *J Hypertension*, Vol. 4, pp. 283-287, 1986.
10. D.S. Goldstein, **R. Zimlichman**, R.W. Stull, H.R. Keiser, I.J. Kopin. Estimation of intrasynaptic norepinephrine concentration in man. *Hypertension*, Vol 8, pp. 471-475, 1986.
11. **R. Zimlichman**, D.S. Goldstein, R.W. Stull, C.J. Folio, H.R. Keiser. Dietary salt intake and the clonidine suppression test. *J Clin Pharmacol*, Vol. 27, pp. 199-205, 1987.
12. D.S. Goldstein, R.O. III Cannon, **R. Zimlichman**, H.R. Keiser. Clinical evaluation of Impedance Cardiography. *Clin Physiol*, Vol. 6, pp. 235-251, 1986.
13. D.S. Goldstein, **R. Zimlichman**, R.W. Stull, H.R. Keiser. Plasma catecholamines and hemodynamic responses during isoproterenol infusions in man. *Clin Pharmacol Therapy*, Vol. 40, 233-238, 1986.
14. **R. Zimlichman**, D.S. Goldstein, G. Eisenhoffer, G. Kelly, R.W. Stull, H.R. Keiser. Comparison of renal removal of norepinephrine and isoproterenol in dogs. *Clin Exp Pharmacol Physiol*, Vol. 13, pp. 777-781, 1986.
15. **R. Zimlichman**, D.S. Goldstein, S. Zimlichman, H.R. Keiser. Effects of ouabain on cytosolic calcium in lymphocytes, platelets, and cultured adrenomedullary cells. *J Hypertension*, Vol. 5, pp. 605-609, 1987.

16. **R. Zimlichman**, H.R. Keiser, H.B. Pollard, E. Heldman.
Calcium influx but not cytosolic calcium level triggers exocytotic secretion in cultured bovine adrenomedullary cells.
J Hypertension, Vol. 4 (suppl 6), pp. S203-S205, 1986.
17. **R. Zimlichman**, D.S. Goldstein, S. Zimlichman, R.W. Stull, H.R. Keiser.
Angiotensin II increases cytosolic calcium and stimulates catecholamine release in cultured bovine adrenomedullary cells.
Cell Calcium, Vol. 8, pp. 315-325, 1987.
18. D.S. Goldstein, **R. Zimlichman**, G.D. Kelly, R.W. Stull, J.D. Bacher, H.R. Keiser.
Effect of ganglion blockade on cerebrospinal fluid norepinephrine.
J. Neurochem, Vol. 49, pp. 1484-1490, 1987.
19. M.J. Jaffe, P.D. Levinson, **R. Zimlichman**, J.C. Cohen, C.N. Karson, F.M. De Monasterio.
The effect of metoclopramide on the ganzfeld electroretinogram.
Vision Res, Vol. 27, pp. 1693-1700, 1987.
20. P.D. Levinson, **R. Zimlichman**, D.S. Goldstein, H.R. Keiser.
Antihypertensive therapy with Ketanserin: metabolic and hemodynamic effects.
J. Cardiovascular Pharmacol, Vol. 12, pp. 384-389, 1988.
21. **R. Zimlichman**, P.D. Levinson, G. Kelly, R.W. Stull, H.R. Keiser, D.S. Goldstein.
Derivation of urinary dopamine from plasma dihydroxyphenylalanine.
Clin Sci, Vol. 75, pp. 515-520, 1988.
22. **R. Zimlichman**, D. Mossinson, I.A. Ovsyshcher.
Assesment of hemodynamic changes in the early phase of uncomplicated acute myocardial infarction.
International J Cardiol, Vol 25, pp. 303-312, 1989.
23. Y. Frenkel, G. Barkai, S. Mashiach, E. Dolev, **R. Zimlichman**, M. Weiss.
Hypocalciuria of preeclampsia is independent of parathyroid hormone and of 1,25, dihydroxy D3 levels.
Am J Obstet Gynecol, 77:689-691, 1991.
24. M. Weiss, J. Zaretsky, **R. Zimlichman**, N. Somorodinsky, A.S. Dion, J. Kedar, J.H. Wreshner.
Expression of a gene coding for breast tumor associated antigen in thyroid papillary carcinoma. Cancer Letters, 58: 125-130, 1991.
25. I. Kobrin, P. Guntzel, R. Viskoper, E. Paran, **R. Zimlichman**.
Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension. Drugs 41 (Suppl.1) 31-36, 1991.
26. P. Guntzel, I. Kobrin, C. Pasquier, **R. Zimlichman**, J.R. Viskoper.

The effect of cilazapril a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients.
J Cardiovasc Pharmacol 17:8-12, 1991.

27. M. Weiss, B. Milman, B. Rosen, Z. Eisentstein, **R. Zimlichman**.
Analysis of the diminished skin perfusion in elderly people by laser doppler flowmetry.
Age and Ageing 21:237- 241, 1992.

28. I.A. Ovsyshcher, **R. Zimlichman**, Katz A, Ch. Bondy, S. Furman.
Measurments of cardiac output by impedance cardiography in pacemaker patients at rest: effects of various AV delays.
J Am Coll Cardiol 21:761-767, 1993.

29. M. Weiss, B. Milman, B. Rosen, **R. Zimlichman**. Quantitation of thyroid hormone effect on skin perfusion by laser Doppler flowmetry. J Clin Endocrinol Metab 76:680-2, 1993.

30. Y. Yodfat, **R. Zimlichman**.
Dose finding and dose justification of once daily cilazapril in combination with hydrochlorothiazide in non-obese patients with mild to moderate hypertension.
J of Drug Development 6:117-121, 1994.

31. J. Barg, M.M. Belcheva, **R. Zimlichman**, R. Levy, D. Saya, R.J. McHale, F.E. Johnson, C.J. Coscia, Z. Vogel.
Opioids inhibit endothelin- mediated DNA synthesis, phophatidyl turnover and Ca⁺⁺ mobilization in rat C6 glioma cells.
J Neurosci 14:5858-5864, 1994.

32. J. Barg J, M.M. Belcheva, **R. Zimlichman**, R. Levy, D. Saya, R.J. McHale, F.E. Johnsonn, C.J. Coscia, Z. Vogel.
Opioids inhibit intracellular Ca⁺⁺ mobilization in rat C6 glioma cells. Regulatory peptides, 54:15-16, 1994.

33. **R. Zimlichman**, D. Zilberman, B. Gold.
Hemodynamic effects of nisoldipine in young hypertensive patients.
Isr J Med Sci, 31:288-292, 1995.

34. **R. Zimlichman**, L. Zeidel, D. Gefel, J. Barg, C. Shahar, I. Nakash, Z. Matas, S. Gaas, H.E. Eliahou.
Insulin induces medial hypertrophy of myocardial arterioles in rats.
Am J Hypertension, 8:915-920, 1995.

35. **R. Zimlichman**, Z. Matas, S. Gass, C. Shahar, Barg J, I. Nakash, L. Zeidel, H.E. Eliahou. Hyperinsulinemia increases blood pressure in genetically predisposed SHR but not in normotensive WKY rats. *J Hypertension*, 13:1009-1013, 1995.
36. **R. Zimlichman**, D. Gefel, H.E. Eliahou, Z. Matas, B. Rosen, S. Gass, C. Ela, Y. Eilam, Z. Vogel, J. Barg. Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats, *Circulation*, 93:1020-1025, 1996.
37. E. Heldman, J. Barg, A. Fisher, R. Levy, Z. Pittel, **R. Zimlichman**, M. Kushnir, Z. Vogel. Pharmacological basis for functional selectivity of partial muscarinic receptor agonists. *Eur J Pharmacol*, 297:283-291,1996.
38. E. Heldman, J. Barg, Z. Vogel, H.B. Pollard, **R. Zimlichman**. Correlation between secretagogue- induced Ca influx, intracellular calcium levels and secretion of catecholamines in cultured adrenal chromaffin cells. *Neurochem Int*, 28: 325-334, 1996.
39. **R. Zimlichman**, L. Zaidel, S. Nofach-Mozes, A. Shkedy, Z. Matas, C. Shahar, H.E. Eliahou. Hyperinsulinemia induces myocardial infarctions and arteriolar medial hypertrophy in spontaneously hypertensive rats. *Am J Hypertens*, 10: 646-653, 1997.
40. **R. Zimlichman**, J. Schwartz, R Tobar. Rest and effort hemodynamic responses during prolonged treatment with felodipine, 24-hour blood pressure monitoring and echocardiographic changes. *Am J Hypertens*, 10:905-912, 1997.
41. Z. Madar, E. Cohen- Melamed, **R. Zimlichman**. Acarbose reduces blood pressure in sucrose-induced hypertension in rats. *Isr J. Med Sci*, 33:153-159, 1997.
42. S. Carney, L. Wing, A. Riberio, R. Kallwellis, **R. Zimlichman**, R. J. Viskoper, D. Mion Jr, I. Kobrin. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. *J of Human Hypertension*, 11: 459-466, 1997.
43. B. Rosen, J. Barg, **R. Zimlichman**. Effect of angiotensin II, endothelin-1 and protein kinase C inhibitor on DNA synthesis and intracellular calcium mobilization in vascular smooth muscle cells from young normotensive and spontaneously hypertensive rats. *Am J Hypertens* 12:1243-1251,1999.
44. **R. Zimlichman**. The Israeli experience with Ocsaar (Losartan) an experience of treatment of 421 patients in the community. *Harefuah (Medicine Isr)*, 137:597-603, 1999.

45. D. El-Ani, KA Jacobson, **R. Zimlichman**, A. Katz, A. Shainberg. Uptake of glucose analogs reflects the rate of contraction of cultured myocytes. J Basic Clin Physiol Pharmacol, 10:287-303, 1999.
46. **R. Zimlichman**. The Israeli experience in treatment with Cilazapril in the community clinics in Israel. Harefuah (Medicine Isr.), 138:345-350, 2000.
47. E. Grossman, A. Grossman, MH. Schein, **R. Zimlichman**, D. Gavish. Breathing-control lowers blood pressure. J. Hum Hypertens. 15: 263-269.2001.
48. E. Leibovitz, N. Hazanov, **R. Zimlichman**, M. Shargorodsky, D. Gavish. Treatment with Atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 14:1096-1098, 2001.
49. H. Eliahou, I. Avinoach, M. Shahmurov, A. Ben-David, C. Shahar, Z. Matas. **R. Zimlichman**. Renoprotective effect of angiotensin II receptor antagonists in experimental chronic renal failure. Am J Nephrol 21: 78-83, 2001.
50. K. Reinhart, T. Menges, B. Gradlund, J-H. Zwaveling, M. Smithes, J-L. Vincent, J.m. Tellado Rodriguez, A. Salgado-Remigio, **R. Zimlichman**, S. Withington, K. Tschaikowsky, R. Brase, P. Damas, H. Kupper, J. Kempeni, J. Eiselsten, M. Kaul. Randomized placebo-controlled trial of the anti-TNF-a antibody fragment afelimomab in hyperinflammatory response in severe sepsis: The RAMSES Study. Crit Care Med, 2001;29:765-769.
51. D. El-Ani, **R. Zimlichman**. Simvastatin induces apoptosis of cultured rat cardiomyocytes. J Basic Clin Physiol Pharmacol. 2001;12:325-38.
52. D. Gavish, E. Leibovitz, I Elly, M. Shargorodsky, **R. Zimlichman**. Follow up in a lipid clinic improves the management of risk factors in CVD patients. Isr Med Assoc J, 2002;4:694-7 (Impact Factor 0.510, 78/103, Medicine, General & Internal)
53. M. Shargorodsky, E. Leibovitz, L. Lubimov, D. Gavish, **R. Zimlichman**. Prolonged treatment with the AT1 receptor blocker, Valsartan increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens. 2002 Dec;15:1087-91. (Impact Factor 3.116, 17/52, Peripheral Vascular Disease).
54. E. Kaluski, I. Kobrin, **R. Zimlichman**, A. Marmor, O. Krakov, O. Milo, A. Frey, S. Kaplan, R. Krakover, A Caspi, Z Vered, G Cotter. RITZ 5: Randomized Intravenous Tezosentan (An endothelin ET-A/B Antagonist) for the treatment of pulmonary edema. A prospective, Multicenter, double blind Placebo Controlled Study. J.Am.Coll Cardiol 2003, 41:204-10 (Impact Factor 9.701, 3/74, Cardiac & Cardiovascular Systems)

- 54.a (-) Kaluski E., Kobrin I., **R. Zimlichman**. RITZ-5: Randomized Intravenous TeZosentan (an endothelin-A/B antagonis) for the treatment of Pulmonary Edema. A prospective, Multicenter, Double-blind, Placebo-Controlled Study. ACC. Current Journal Review, J Am. Coll Cardiol, 2003 Jan 15;41(2):204-10. (Impact Factor 9.701, 3/74, Cardiac & Cardiovascular Systems)
55. G. Cotter, C.F. Cannon, C.H. McCabe, Y. Michovitz, E. Kaluski, A. Charlesworth, O. Milo, J. Bentley, A. Blatt, R. Krakover, **R. Zimlichman**, L. Reisin, A. Marmor, B. Lewis, Z. Vered, A. Caspi, E. Braunwald. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes- Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J 2003;145:622-7.(Impact Factor 3.514, 13/74, Cardiac & Cardiovascular Systems).
56. M. Shargorodsky, J. Wainstein, D. Gavish , E. Leibovitz, Z. Matas, **R. Zimlichman** Treatment with Rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003 Aug;16(8):617-22. (Impact Factor 3.116, 17/52, Peripheral Vascular Disease)
57. E.Leibovitz, M.Beniashvili, **R.Zimlichman**, A.Freiman, M.Shargorodsky, D.Gavish. Treatment with amlodipine and atorvastatine have additive effects in improving arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 2003 Sep;16(9):715-8. . (Impact Factor 3.116, 17/52, Peripheral Vascular Disease)
58. D.El Ani, **R.Zimlichman**, TNF-alpha stimulates ATP-sensitive potassium channels and attenuated deoxyglucose and Ca uptake of H9c2 cardiomyocytes. Ann N Y Acad Sci 2003 Dec;1010:716-20.(Impact Factor 1.930, 7/50 Multidisciplinary Sciences).
59. A.Sherman , A.Frimerman, D.Zabeeda, S.Ezra, A.Sidi, **R.Zimlichman**, T.Ezri estimation of volume and hemodynamic changes during transurethral Resection of (TURP). The Internet Journal of Anesthesiology 2003;Volume 7,Number 1.
60. A.Lubetsky, A.Hoffman, A.Eldor, **R.Zimlichman**, V.Kostenko, B.Brenner. Efficacy and safety of a prothrombin complex concentrate (Octaplex[®]) for rapid reversal of oral anticoagulation. Thromb Res. 2004;113(6):371-8. (Impact Factor 2,508, 35/61, Hematology, Impact Factor 2.058, 50/52, Vascular Diseases).
61. **R.Zimlichman**, M.Shargorodsky, M.Boaz, D.Duprez, K.H.Rahn, D.Rizzoni A.Coca Payeras, C.Hamm, G.McVeigh. Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 system: Reliability, repeatability, and establishment of normal values for healthy European population—

the Seven European Sites Study (SESS). Am J Hypertens. 2005 Jan;18(1):65-71. (Impact Factor 3.116, 17/52, Peripheral Vascular Disease).

62. Y.Sharabi, **R.Zimlichman**, R.Mansouri.,J. Chun, D.S.Goldstein. Does acetylcholinesterase inhibition affect catecholamine secretion by adrenomedullary cells? IMAJ – The Israel Medical Association Journal 2004 Jul;6(7):396-399.(Impact Factor 0.510, 78/103, Medicine, General & Internal).
63. Y. Sharabi, **R. Zimlichman**, S. Alesci, T. Huynh, R. Mansouri, J. Chun, S.Perera, K. Pacak, D.S. Goldstein. Glucagon does not Affect Catecholamine Release in Primary Cultures of Bovine Adrenal Chromaffin Cells. Horm Metab. Res 2005 Apr; 37(4):205-208. (Impact Factor 1.997, 58/93, Endocrinology & Metabolism)
64. T.Ezri, I.Zahalka, D.Zabeeda, Z.Feldbrin, A.Eidelman, **R.Zimlichman**., B.Medalion, S.Evron. Similar incidence of hypotension with combined spinal-epidural alone for knee arthroplasty. Canadian Journal of Anesthesia 2006 Feb; 53 (2) :139-145. (Impact Factor 1.976, 9/22, Anesthesiology).
65. E. Leshinsky-Silver, S. Cheng, A.Michael, S.Shwartz, L.Scharf, D.Lev, M.Boaz, D.Brunner and **R.Zimlichman**. Candidate Gene Polymorphism in Cardiovascular disease: The BIP Cohort. IMAJ – (Israel Medical Association Journal): 2006 Feb; 8 (2) :103-105. (Impact Factor 0.510, 78/103, Medicine, General & Internal).
66. M.Shargorodsky, S.Serov, E.Leibovitz, D.Gavish, D.Harpaz, **R.Zimlichman**. Long term Thyrotropin suppressive Therapy with Levothyroxin impairs small and large artery elasticity and increases left ventricular mass in asymptomatic athyreotic patients. Mary Ann Liebert, Inc., Thyroid 2006 Apr; 16: (4): 381-386. (Impact Factor 1.920, 60/93, Endocrinology & Metabolism).

67. T.Ezri, N.Issa, D.Zabeeda, B.Medalion, A. A.Tsivian, **R.Zimlichman**, P.Szmuk, S.Evron. Comparison of hemodynamic profiles in transurethral resection of prostate versus transurethral resection of urinary bladder tumors under spinal anesthesia: a bioimpedance study. *Journal of Clinical Anesthesia* 2006 Jun; 18(4): 245-250. (Impact Factor 1.028, 16/22, Anesthesiology).
68. Y. Aloni, S.Evron, T.Ezri, B.Medalion, M.Protianov, P.Szmuk, **R.Zimlichman**, M.Muggia-Sullam. Morbidly Obese Patients are Hemodynamically stable during Laparoscopic Surgery: A thoracic bioimpedance study. *Journal of Clinical Monitoring and Computing* 2006 Aug; 20(4): 261-266.
69. M.Shargorodsky, A.Fleed, M.Boaz, D.Gavish, **R.Zimlichman**. The Effect of a rapid weight loss induced by laparoscopic adjustable gastric banding on arterial stiffness, metabolic and inflammatory parameters in patients with morbid obesity. *Int. J. Obesity*, 2006;Nov;30(11):1632-8. (Impact Factor 4.055, 21/93, Endocrinology & Metabolism)
70. D. Tanne, M. Benderly, U. Goldbourt, M. Haim, A. Tenenbaum, EZ. Fisman, Z. Matas, Y. Adler, **R. Zimlichman**, S. Behar. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. *Stroke*, 2006; 37: 1720-1724. (Impact Factor 5.391, 7/52, Peripheral Vascular Disease).
71. AB. Jotkowitz, A. Porath, A. Shotan, M. Mittleman, E. Grossman, **R. Zimlichman**, BS. Lewis, A. Caspi, S, Gottlieb, M. Garty. Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey. *Isr. Med. Assoc. J.*, 2006; 8: 875-879. (Impact Factor 0.510, 78/103, Medicine, General & Internal).
72. M. Benderly, M. Haim, V. Boyko, D. Tanne, S. Behar, **R. Zimlichman**, U. Goldbourt.C-Reactive Protein Distribution and Correlates among Men and Women with Chronic coronary Heart Disease. *Cardiology*, 2007 Feb;1074 (4):345-353. (Impact Factor 1,795, 34/74, Cardiac & Cardiovascular Systems).
73. M. Shargorodsky, M. Boaz, I. Davidovitz, J. Asherov, D. Gavish, **R. Zimlichman**. Treatment of Hypertension with Thiazides:Benefit or Damage Effect of Low-and High-Dose Thiazide Diuretics on Arterial Elasticity and Metabolic Parameters in Hypertensive Patients with and without glucose Intolerance. *Journal of Cardio Metabolic Syndrome*, 2007; 2 (1):16-23.
74. M. Garty, A.Shotan, S.Gotlieb, M. Mittelman, A. Porath, B. S. Lewis, E. Grossman, S. Behar, J. Leor, M. S. Green, **R. Zimlichman**, A. Caspi. The Management, Early and one year outcome in Hospitalized patients with heart Failure: A National heart

Failure survey in Israel – HFSIS 2003. IMAJ, April 2007, 9:227-232. (Impact Factor 0.510, 78/103, Medicine, General & Internal).

75. B.S. Lewis, A. Shotan, S. Gottlieb, S. Behar, D.A. Halon, V. Boyko, J. Leor, E. Grossman, **R. Zimlichman** A. Porath, M. Mittleman, A. Caspi and M. Garty. Late Mortality and Determinants in Patients with heart Failure and preserved Systolic Left Ventricular Function: The Israel Nationwide heart Failure Survey. IMAJ, April 2007, 9:234-238. (Impact Factor 0.510, 78/103, Medicine, General & Internal).
76. A. Tanay, E. Leibovitz, A. Frayman, **R. Zimlichman**, M. Shargorodsky, D. Gavish. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann NY Acad Sci.2007 June; 1108:24-34. Ann NY Acad Sci. 2007; 1114:464.
77. M. Shargorodsky, E. Hass, M. Boaz, D. Gavish, **R. Zimlichman**. High dose treatment with angiotensin II receptor blocker in patients with hypertension: Differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 197, 2007, June, 303-310. (Impact Factor 3.811, 12/52, Peripheral Vascular Disease).
78. D. El-Ani, **R. Zimlichman**, Y. Maschiach, A. Shainberg. Adenosine and TNF-alpha exert similar inotropic effect on heart cultures suggesting a cardioprotective mechanism against hypoxia. Life Sci. 2007, Aug. 16;81 (10):803-813. (Impact Factor 2.389, 28/76, Medicine, Research & Experimental).
79. E. Kaluski, G. cotter, M. Leitman, O. Milo-Cotter, R. Krakover, I. Kobrin, T. Moriconi, M. Rainisio, A. Caspi, L. Reizin, **R. Zimlichman**, Z. Vered. Clinical and Hemodynamic Effects of Bosentan Dose Optimization in symptomatic Heart Failure patients with Severe Systolic dysfunction, Associated with Secondary Pulmonary Hypertension – A Multi Center Randomized Study. Cardiology, 2007 Sep. 17; 109 (4):273-280. (Impact Factor 1.795, 34/74, Cardiac & Cardiovascular Systems).
80. M. Shargorodsky, K. Michaelova, M. Boaz, D. Gavish, **R. Zimlichman**. Effect of long-term treatment with Rosiglitazone on arterial elasticity and metabolic parameters in Patients with Type 2 diabetes Mellitus: A two year follow up Study. Diabetic Medicine, 2007 Nov; 24(11):1254-60. (Impact Factor 2.489, 45/93, Endocrinology & Metabolism).
81. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T,

Rainisio M, Caspi A, Reizin L, **Zimlichman R**, Vered Z. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.

Cardiology, 2008;109 (4):273-80. Epub 2007 Sep 17.

82. Shotan A, Garty M, Blondheim DS, Meisel SR, Lewis BS, Shochat M, Grossman E, Porath A, Boyko V, **Zimlichman R**, Caspi A, Gottlieb S; HFSIS Steering Committee and Investigators. Eur Heart J. 2010 Feb;31(3):309-17.

83. Vogt L, Chiurciu C, Chadha-Boreham H, Danaietash P, Dingemans J, Hadjadj S, Krum H, Navis G, Neuhart E, Parvanova AI, Ruggenenti P, Woittiez AJ, **Zimlichman R**, Remuzzi G, de Zeeuw D; PROLONG (PROteinuria Lowering with urOteNsin receptor antaGonists) Study Group. Effect of Urotensin Receptor Antagonist Palosuran in Hypertensive Patients with Type-2 Diabetic Nephropathy. Hypertension. 2010 May;55(5):1206-9. Epub 2010 Mar 15.

84. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes. Cernes R, **Zimlichman R**, Shargorodsky M. Adv Cardiol. 2008;45:65-81.

85. Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Shargorodsky M, Debby O, Matas Z, **Zimlichman R**.

Nutr Metab (Lond). 2010 Jul 6;7:55.

86. Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Vogt L, Chiurciu C, Chadha-Boreham H, Danaietash P, Dingemans J, Hadjadj S, Krum H, Navis G, Neuhart E, Parvanova AI, Ruggenenti P, Woittiez AJ, **Zimlichman R**, Remuzzi G, de Zeeuw D; PROLONG (PROteinuria

Lowering with urOteNsin receptor antaGonists) Study Group. Hypertension. 2010 May;55(5):1206-9. Epub 2010 Mar 15.

87. Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: results from heart failure survey in Israel (HFSIS). Shotan A, Garty M, Blondhein DS, Meisel SR, Lewis BS, Shochat M, Grossman E, Porath A, Boyko V, **Zimlichman R**, Caspi A, Gottlieb S; HFSIS Steering Committee and Investigators. Eur Heart J. 2010 Feb;31(3):309-17. Epub 2009 Oct 15.

88. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Cernes R, Mashavi M, **Zimlichman R**. Vasc Health Risk Manag. 2011;7:749-59. Epub 2011 Dec 12. Review.

94. Effect of Long-Term L-Arginine Supplementation on Arterial Compliance and Metabolic Parameters in Patients with Multiple Cardiovascular risk Factors: Randomized, Placebo-Controlled Study. Guttman H, **Zimlichman R**, Boaz M, Matas Z, Shargorodsky M. J Cardiovasc Pharmacol. 2010 Jun 7. [Epub ahead of print].

95. Arterial elasticity in obese subjects with coronary slow flow phenomenon. Hussein O, Zidan J, Plich M, Gefen H, Klein R, Shestatski K, Abu-Jabal K, **Zimlichman R**. Isr Med Assoc J. 2013 Dec;15(12):753-7.

96. Treatment of Hypertension and Metabolic Syndrome: Lowering Blood Pressure is not enough for Organ Protection, New Approach- Arterial Destiffening. Curr Hypertens Report, 2014;16:479-483.

97. Efficacy and safety of the Dual L- and T- type calcium channel blocker ACT-280778: a proof of concept study in patients with mild to moderate essential hypertension. Dingemans J, Otasevic P, Shakeri-Nejad K, Klainman E, Putnikovic B, Kracker H, Mueller MS, **Zimlichman R**. Journal of Human Hypertension, 2014 1-7.

98. RESPeRATE: the role of paced breathing in hypertension treatment. Cernes R, **Zimlichman R**. J Am Soc Hypertens. 2015 Jan;9(1):38-47. doi: 10.1016/j.jash.2014.10.002. Epub 2014 Oct 16.

99. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society.

Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent S, Lekakis J, Mikhailidis DP, Naka KK, Protogerou AD, Rizzoni D, Schmidt-Trucksäss A, Van Bortel L, Weber T, Yamashina A, **Zimlichman R**,

Reviewers: Boutouyrie P, Cockcroft J, O'Rourke M, Park JB, Schillaci G, Sillesen H, Townsend RR.

Atherosclerosis. 2015 May 16;241(2):507-532. doi:

10.1016/j.atherosclerosis.2015.05.007. [Epub ahead of print] Review.

100. Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease.

Benderly M, Sapir B, Kalter-Lebovici O, Zimlichman R. Biomarkers, April 21, 2016, 1-6.

Publications of Participation in Clinical Studies, adjudications and committees:

1. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. *J Card Fail.* 2008 Oct;14(8):631-40. Epub 2008 Sep 14.

2. Apixaban versus warfarin in patients with atrial fibrillation. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Gerald M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. *N Engl J Med.* 2011 Sep 15;365(11):981-92. Epub 2011 Aug 27.

3. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. *N Engl J Med.* 2011 Sep 8;365(10):883-91. Epub 2011 Aug 10.

4. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M; Pre-RELAX-AHF study group. *Eur J Heart Fail.* 2011 Sep;13(9):961-7. Epub 2011 May 28.

5. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, Budaj A, Niemelä M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR; RIVAL trial group. Lancet. 2011 Apr 23;377 (9775):1409-20. Epub 2011 Apr 4. Erratum in: Lancet. 2011 Jul 2;378 (9785):30. Lancet. 2011 Apr 23;377 (9775):1408.

6. Apixaban in patients with atrial fibrillation. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanus-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. N Engl J Med. 2011 Mar 3;364(9):806-17. Epub 2011 Feb 10.

7. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.

Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. N Engl J Med. 2010 Oct 7;363(15):1419-28.

8. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. N Engl J Med. 2010 Sep 2;363(10):930-42. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.

9. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators. Lancet. 2010 Oct 9;376(9748):1233-43.
10. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. Weatherley BD, Cotter G, Dittrich HC, DeLuca P, Mansoor GA, Bloomfield DM, Ponikowski P, O'Connor CM, Metra M, Massie BM; PROTECT Steering Committee, Investigators, and Coordinators. J Card Fail. 2010 Jan;16(1):25-35. Epub 2009 Dec 11.
11. Dabigatran versus warfarin in patients with atrial fibrillation. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. N Engl J Med. 2009 Sep 17;361(12):1139-51. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.
12. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Circulation. 2009 Jun 9;119(22):2877-85. Epub 2009 May 26.

13. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. N Engl J Med. 2009 May 14;360(20):2066-78. Epub 2009 Mar 31. 1-Jul-1514.
14. Effect of dronedarone on cardiovascular events in atrial fibrillation. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. N Engl J Med. 2009 Feb 12;360(7):668-78. Erratum in: N Engl J Med. 2009 Jun 4;360(23):2487. N Engl J Med. 2011 Apr 14;364(15):1481.
15. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators, and Coordinators. J Card Fail. 2008 Oct;14(8):631-40. Epub 2008 Sep 14.
16. Basal insulin and cardiovascular and other outcomes in dysglycemia. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. N Engl J Med. 2012 Jul 26;367(4):319-28. Epub 2012 Jun 11.
17. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggioni AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. N Engl J Med. 2012 Jul 26;367(4):309-18. Epub 2012 Jun 11.
18. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Lancet Neurol. 2012 Jun;11(6):503-11. Epub 2012 May 8.

19. Vorapaxar in the secondary prevention of atherothrombotic events. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators. *N Engl J Med.* 2012 Apr 12;366(15):1404-13. Epub 2012 Mar 24.

20. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators. *Lancet Neurol.* 2012 Apr;11(4):315-22. Epub 2012 Mar 7.

21. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S; AVERROES Steering Committee and Investigators. *Lancet Neurol.* 2012 Mar;11(3):225-31. Epub 2012 Feb 1.

22. Subclinical atrial fibrillation and the risk of stroke. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. *N Engl J Med.* 2012 Jan 12;366(2):120-9.

23. Dronedarone in high-risk permanent atrial fibrillation. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggreffe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaiz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanan F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PALLAS Investigators. *N Engl J Med.* 2011 Dec 15;365(24):2268-76. Epub 2011 Nov 14. Erratum in: *N Engl J Med.* 2012 Feb 16;366(7):672.

24. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. *N Engl J Med.* 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

25. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P.

N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

26. [Oral apixaban for the treatment of acute venous thromboembolism.](#)

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators.

N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.

27. [Treatment of anemia with darbepoetin alfa in systolic heart failure.](#)

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

28. [Rivaroxaban for thromboprophylaxis in acutely ill medical patients.](#)

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

29. [Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial \(RED-HF\).](#)

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators.

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.

30. [Apixaban for extended treatment of venous thromboembolism.](#)

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; PLIFY-EXT Investigators.

N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.

31. [Basal insulin and cardiovascular and other outcomes in dysglycemia.](#)

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

32. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators.

J Am Heart Assoc. 2016 Mar 8;5(3). pii: e002197. doi: 10.1161/JAHA.115.002197.

33. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzylo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.

34. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.

35. Interaction between digoxin and dronedarone in the PALLAS trial. Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ; PALLAS investigators. Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1019-25. doi: 10.1161/CIRCEP.114.002046. Epub 2014 Nov 6.

36. Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension. Dingemans J, Otasevic P, Shakeri-Nejad K, Klainman E, Putnikovic B, Kracker H, Mueller MS, Zimlichman R. J Hum Hypertens. 2015 Apr;29(4):229-35. doi: 10.1038/jhh.2014.79. Epub 2014 Sep 18.

37. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators. Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

38. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T; REVIVE Heart Failure Study Group. JACC Heart Fail. 2013 Apr;1(2):103-11. doi: 10.1016/j.jchf.2012.12.004. Epub 2013 Apr 1.

B-2. CASE REPORTS

1. **R. Zimlichman**, M.N. Leventhal, A. Baumgarten. Pyomyositis, case report and review. Harefuah (Medicine Isr.), Vol. 102, pp. 328-329, 1982.
2. **R. Zimlichman**, M. Goligorsky, M. Zlotnic. Idiopathic edema associated with diuretics. Harefuah (Medicine Isr.), Vol. 104, pp. 229-230, 1983.
3. **R. Zimlichman**, J. Rapaport, M. Zlotnic. Kaposi sarcoma after kidney transplantation, regression following discontinuation of Azathioprine therapy. Harefuah (Medicine Isr.), Vol. 105, pp. 118-119, 1983.
4. **R. Zimlichman**, I.A. Ovsyscher. Torsades de pointes and carcinoma: a case report with brief review of the causes of delayed repolarization arrhythmias. Isr J Med Sci, Vol. 21, pp. 79-82, 1985.
5. **R. Zimlichman**, A. Porat, R. Sobel. Bromocriptine responsive idiopathic edema. Isr J Med Sci, Vol. 20, pp. 264-266, 1984.
6. L. Krugliak, **R. Zimlichman**, F. Schlaeffer, M. Sachs. Angioimmunoblastic lymphoma and thymic epithelial hyperplasia in angioimmunoblastic lymphadenopathy following gold therapy. Isr J Med Sci, Vol. 21, pp. 381-385, 1985.
7. B. Rosen, I.A. Ovsyshcher, **R. Zimlichman**. Complete atrioventricular block Induced by methyl dopa. Pace, Vol. 11, pp. 1555-1558, 1988.
8. **R. Zimlichman**, J.L. Bami, R. Sobel. Anterior pituitary insufficiency with hyperprolactinemia, normal sella turcica and SIADH as a manifestation of Hypotalamic metastases of occult carcinoma. Medical Rounds Vol 3, pp. 90-94, 1990.
9. C. Butnaru. D. Zilberman, **R. Zimlichman**. Intravenous treatment with gammaglobulin in pregnancy-case report and review of literature. Harefuah (Medicine Isr.), Vol. 117, pp. 58-61, 1989.
10. V. Guetta, A. Morbel, **R. Zimlichman**. Brucella Pericarditis with pericardial tamponade. Eur J Int Med, Vol 1, pp. 165-166 1989.
11. **R. Zimlichman**, D. Amital-Negrea, B. Vestfrid, D. Zilberman, H. Reuveni. Severe multisystemic toxicity associated with cutaneous contact with solution of sulfonamide and pyrimethamine. Eur J Int Med, Vol 1, pp. 317-320, 1990.
12. B. Rosen, J. Goldstein, **R. Zimlichman**. Paradoxical embolism. Eur J Int Med, Vol 1, pp. 285-288, 1990

13. A.E. Buchs, **R. Zimlichman**, B. Goldfarb, E. Sikuler. Murine typhus endocarditis; a report of a case. South Med J, Vol 85, pp.751-753, 1992.
14. B. Rosen, M. Weiss, B. Milman, L. Zajdel, A. Goor, **R. Zimlichman**. Carotid body tumor- case report and review of diagnostic and therapeutic approach. South Med J, Vol 85, pp.756-759, 1992.
15. M.N. Leventhal, **R. Zimlichman**. Resolution of hypertensive retinopathy despite persistent hypertension. South Med J, Vol 86, pp.190-194, 1993.
16. Strugo R, Tobar R, **Zimlichman R**. Psoas abscess, case report and review of the literature, Harefuah (Medicine, Isr), Vol 128, pp.216-219, 1995.

17. Y. Davidovitz, R. Zimlichman, E. Rozner, M. Berkovitz, A. Ballin, D. Meytes. Deletion of the long arm chromosome 7 in myelomonocytic leukemia with bone marrow eosinophilia. Cancer Genet Cytogenet 97:122-124, 1997.
18. O.Yossefovitch, T.Gotesman, M.Assous, E.Marva, **R.Zimlichman**, M.Dan. Opisthorchiasis from imported raw fish. Emerg Infect Dis.,10: (12): 2122-6, 2004.

B-3. REVIEW ARTICLES

1. **R. Zimlichman**, C. Chaimovitz. Idiopathic edema, editorial. Harefuah (Medicine Isr.), Vol. 104, pp. 254-256, 1983.
2. **R. Zimlichman**, C. Chamovitz. The treatment of end stage diabetic nephropathy. Harefuah (Medicine Isr.), Vol. 104, pp. 103-106, 1983.
3. **R. Zimlichman**, Y. Chaitchenko. Hypertension in chronic renal failure, hemodynamics and pathogenesis. Harefuah (Medicine Isr.), Vol. 105, pp. 329-331, 1983.
4. **R. Zimlichman**, C. Chaimovitz. Hemodynamic changes in essential hypertension, review. Harefuah (Medicine Isr.), Vol. 105, pp. 278-280, 1983.
5. **R. Zimlichman**, S. Feldman, M. Zlotnic, C. Chaimovitz. Our experience in continuous ambulatory peritoneal dialysis. Harefuah (Medicine Isr.), Vol. 105, pp. 205-208, 1983.
- 6a. **R. Zimlichman**, I.A. Ovsyshcher. Infective endocarditis in hypertrophic cardiomyopathy: case report and review of literature 1961-1982. Mount Sinai J Med, Vol. 51, pp. 614-619, 1984.
- 6b. **R. Zimlichman**, I.A. Ovsyshcher. Infective Endocarditis in hypertrophic cardiomyopathy. Year Book of Medicine p. 101, 1984.
7. **R. Zimlichman**, I.A. Ovsyshcher. Torsades de pointes and carcinoma: a case report with brief review of the causes of delayed repolarization arrhythmias. Isr J Med Sci, Vol. 21, pp. 79-82, 1985.
8. **R. Zimlichman**. Cytosolic calcium in hypertension- invited review. Dialogues in Hypertension, Vol. 2, pp. 4-5, 1987.
9. C. Butnaru, D. Zilberman, **R. Zimlichman**. Intravenous treatment with gammaglobulin in pregnancy- case report and review of literature. Harefuah (Medicine Isr.), Vol. 117, pp. 58-61, 1989.
10. **R. Zimlichman**. Modern approach to evaluation, treatment and follow up of hypertensive patients. Harefuah (Medicine Isr.), Vol 118, pp. 704-707, 1989.
11. **R. Zimlichman**. Angiotensin converting enzyme inhibition in modern treatment of hypertension- Editorial-Review. Isr J Med Sci, Vol 26, pp. 61-61, 1990.
12. **R. Zimlichman**. Treatment of hypertension in our era. Dialogues in Hypertension, invited review, Vol 2, pp. 6-8, 1990.

13. B. Rosen, **R. Zimlichman**. Cerebral autoregulation and the treatment of hypertensive patients with cerebrovascular accident. Harefuah (Medicine Isr.) Vol 118, pp. 24-25, 1990.
 14. **R. Zimlichman**. Modern approach to evaluation treatment and follow up of hypertensive patients. Harefuah (Medicine Isr.) Vol 118, pp. 704-707, 1990.
 15. **R. Zimlichman**. Catecholamines in Hypertension- Update. Dialogues in Hypertension, 5:3-5, 1991.
 16. Rosen, M. Weiss, **R. Zimlichman**. Mechanism of action of Angiotensin converting enzyme inhibitors: role of the kalikrein kinin system and prostaglandins. Harefuah (Medicine Isr) Vol 122, pp.305-308, 1992.
 17. **R. Zimlichman**, Y. Shoenfeld. Insulin resistance- Possible connection between hypertension and coronary artery disease. Harefuah (Medicine Isr), Vol 120, pp.746-749, 1991.
 18. **R. Zimlichman**. Difficulties with cytosolic free calcium measurements. Am J Hypertension, Vol 5, pp.45-46,1992.
-
19. **R. Zimlichman**, Y. Weisbort, Ch. Zakut. Hypertension in pregnancy- pathogenesis and diagnosis. Harefuah (Medicine Isr), Vol 124, pp.696-701, 1993.
 20. **R. Zimlichman**, Y. Weisbort, Ch. Zakut. Hypertension in pregnancy- Therapeutic approach. Harefuah (Medicine Isr), Vol. 125, pp.153-159, 1993.
 21. **R. Zimlichman**, M. Shargorodsky. Herbal treatment- Risks and benefits. Harefuah (Medicine Isr), Vol 126, pp.606-608, 1993.
 22. **R. Zimlichman**. Commentary on Shigetomi and Kuchel's Work on DOPA decarboxylation. Am J Hypertension Vol 6, pp.89-90, 1993.
 23. **R. Zimlichman**. Nisoldipine- Is there a positive inotropic effect? Isr J Med Sci, Vol 30, pp.158-159, 1994.
 24. B. Rosen, **R. Zimlichman**. The value of hypotensive response in stress effort test. Harefuah (Medicine Isr), Vol 126, pp. 533-535, 1994.
 25. Y. Shpirer, J. Asherov, **R. Zimlichman**. Heart disease and respiratory disturbances associated with sleep. Harefuah (Medicine, Isr), 130:551-554, 1996.

26. B. Rosen, **R. Zimlichman**, J. Barg. Endothelin-1. Harefuah (Medicine, Isr), 130:203-207, 1996.
27. Y. Shpirer, J. Asherov, **R. Zimlichman**. Modern use of CPAP. Harefuah (Medicine, Isr), 128:586-590, 1995.
28. D. Gefel, **R. Zimlichman**. Diabetes and smoking. Harefuah (Medicine, Isr), 130:37-40, 1996.
29. **R. Zimlichman**. Peak and trough levels of antihypertensive therapy- new therapeutic approach for prevention of cardiovascular damage. Harefuah (Medicine, Isr), 130:404-406, 1996.
30. D. Gefel, **R. Zimlichman**. Syndrome X. Harefuah (Medicine, Isr), 131:65-68, 1996.

31

ד. גפל, ט. ארבל, ר. צימליכמן
 תיסמונת עמידות לאינסולין - מכנה משותף בהפרעות מאטבוליות שכיחות
 הרפואה, 1996, 131 : 279-275.

32

פ. שטרן, י. דרור, א. אלירז, י. ברג, ר. צימליכמן
 השפעת מעכבי חימצון על הסיכון למחלות לב כליליות
 הרפואה, 1996, 131 : 412-408.

33

ר. צימליכמן
 המהומה של חוסמי הסיידן - לקחים לעתיד
 הרפואה, 1997, 132 : 225-223.

34

ר. צימליכמן, א. צימליכמן
 סילזפריל, תרופה חדשה החוסמת את האנזים המהפך לטיפול ביתר לחץ דם
 Pharmacy Update 1997, 7 : 24-22.

35. **R. Zimlichman**.
 Angiotensin 2 receptor blockade- a new approach to treatment of hypertension.
 Harefuah (Medicine, Isr), 131:43-46, 1996.
36. E. Zimlichman, **R. Zimlichman**.
 Tissue angiotensin 2- physiological importance and therapeutic significance.
 Harefuah (Medicine, Isr), 132: pp.113-116, Jan. 1997.
37. R. Zimlichman. Calcium channel blockers and myocardial infarctions- lessons to the future. Pharmacy Update, 1:21-24, 1996.
38. **R. Zimlichman**.
 The calcium channel blocker dilemma- Questioning the study by Pahor et. al.

Am J Hypertens, 9:1046-1047, 1996.

39. H. Zakut, **R. Zimlichman**, A. Debby, H.E. Eliahou.
Early hemodynamic prediction of intrauterine growth retardation in pregnant hypertensive women. Elsevier Science B.V. 189-198, 1996.
40. H.E. Eliahou, **R. Zimlichman**. Cardio-renal failure. A new name for an old entity. Cardioneurology 4, Editoriale BIOS, 71-73, 1997.

41. R. Zimlichman. New concepts in understanding the hypertensive syndrome-

therapeutic implication Anaesthesia Review/14. Vol. pp.49-56 1998.

42. M. Shargorodsky, **R. Zimlichman**. Primary aldosteronism: The most frequent form of secondary hypertension?. Israeli Medical Association Journal (IMAJ). 4:32-33, 2002.
43. M. Shargorodsky, **R. Zimlichman**. Pheochromocytoma: a disease with many faces. Israeli Medical Association Journal (IMAJ). 4:817-819, 2002.
44. **R. Zimlichman**. Pre-hypertension: A New Old field. Israeli Medical Association Journal (IMAJ) 9: 42-43, 2007.
45. R. Cernes, **R. Zimlichman**, M. Shargorodsky. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes. Adv. Cardiol, 2008; 45:65-81.

B4. CHAPTERS IN BOOKS

1. D.S. Goldstein, P.D. Levinson, **R. Zimlichman**, A. Pitterman, R.W. Stull, H.R. Keiser. Clonidine suppression testing in essential hypertension. In S.M. Weiss K.A. Matthews T. Detre and J.A. Graef (eds.) Stress, reactivity, and cardiovascular disease. NIH publication No 4-2698 pp. 237-244, 1984.
2. E. Baldi, M. Maggi, M.L. De Feo, C.Pupilli, **R. Zimlichman**, E. Forsberg, M. Mannelli. Opioid peptides in human adrenal medulla: Their role in modulation of catecholamine secretion. In: Opioid peptides in blood pressure control. p 103-111. Stumpe KO, Kraft K, Faden AI (eds.). Springer- Verlag, Heidelberg, 1989.
3. E. Heldman, **R. Zimlichman**, M. Levine, L. Raveh, H.B. Pollard. Relationship between catecholamine secretion and distinct calcium fluxes in medullary chromaffin cells. In- Calcium Channel Modulators in Heart and Smooth Muscle- Basic mechanisms and pharmacological aspects. S. Abraham, and G. Amitai eds. VCH Publishers New York, NY, 1990. pp. 87- 104.
4. **R. Zimlichman**, S. Zimlichman, D.S. Goldstein, H.R. Keiser. Angiotensin II regulates catecholamine secretion through a cytosolic calcium dependent mechanism. In- Calcium Channel Modulators in Heart and Smooth Muscle- Basic mechanisms and pharmacological aspects. S. Abraham, and G. Amitai eds. VCH Publishers New York, NY, 1990. pp. 105-116.

5. H.E. Eliahou, M. Ben-Bassat, A. Blau, **R. Zimlichman**. Diabetic nephropathy. p. 77- 84, 1993 in: Diseases affecting the eye and the kidney. L.S. Regenbogen HE Eliahou eds. S. Karger, Basel, Switzerland, 1993.
6. I.A. Ovsyshcher, **R. Zimlichman**, C. Bondy, D. Zilberman, A. Katz, S. Furman. Impedance Cardiography for assessment of implanted cardiac pacemakers. p. 85-92, 1994 in: Thoracic impedance measurements in clinical cardiology, edited by Winter UJ, Klocke RK, Kubicek WG, Niederlag W. Verlag, Stuttgart, New York.

7. H.E. Eliahou, L. Zeidel, . Gefel, J. Barg, C. Shahar, Y. Nakash, Z. Matas, S. Gass, **R. Zimlichman**. Insulin increases arteriolar wall thickness in SHR and WKY rats independently of blood pressure. Cardionephrology, "Il cuore nelle nefropatie e nella dialisi, pp 65-68, 1995. in Editoriale Bios, Cosenza, Italy.
8. H. Zakut, **R. Zimlichman**, A. Debby, HE Eliahou. Early hemodynamic prediction of intrauterine growth retardation in pregnant hypertensive women. in increasingly safe and successful pregnancies, Editors C. Yabes-Almirants, M.B. Luna, Elsevier, pp 189-198, 1996.

9. R. Zimlichman. New concepts in understanding the hypertensive syndrome-

therapeutic implication.

Anaesthesia Review/14. Vol. pp.49-56 1998.

11. R. Cernes, R. Zimlichman, M. Shargorodsky. Arterial elasticity in Cardiovascular disease: Focus on Hypertension, Metabolic Syndrome and Diabetes. Facets. Adv. Cardiol. Basel, Karger, 2008, vol. 45, pp 1-17.
12. R. Cernes, R. Zimlichman. Cardiology Review, Intech, Vol 45, Chapter 4, 2013.

Other Publications

1. ר. צימליכמן – האם יש קשר בין תרופות החוסמות תעלות סידן להתקפי לב? דיון ביקורתי ושיעור לעתיד.
Pharmacy No. 3-4 May, 1996, pp/ 21-24
2. ר. צימליכמן. תמורות מפליגות בתחום הקרדיולוגיה –
בריאות על בוריה
Vol. 63, pp. 36-40, 1998
3. ראובן צימליכמן, ד"ר רלו צ'רנס, ד"ר הילל וירשטל – היפראלדוסטרוניזם ראשוני: שכחות התסמונת וגישה עכשווית להערכתה ולטיפול בה אצל חולי יתר לחץ דם בישראל.
4. Internal Medicine Review
Review No. 49, February, 2004 pp.21-26
5. ר. צימליכמן – טרום יתר לחץ דם Prehypertension מגזין מכון תנובה למחקר גליון 21 מאי 2007

D1. INVITED PAPERS IN SCIENTIFIC MEETINGS

1. DS Goldstein, **R. Zimlichman**, RW Stull, JC Folio, HR Keiser. Measurement of regional neuronal removal of norepinephrine inn man. Presented in the Annual Meeting of the National Council for High Blood Pressure Research. Cleveland, Ohio. September 1985.
2. **R. Zimlichman**. Cytosolic Calcium and Hypertension. Presented in the Israeli Society of Medicine meeting Shefaiim, Israel, Nov 1985.
3. **R. Zimlichman**, DS Goldstein, S Zimlichman, RW Stull, HR Keiser. Angiotensin II increases cytosolic calcium and stimulates catecholamine release in adrenomedullary cells. Presented in the 40th Annual fall Conference of the Council for High Blood Pressure Research. Cleveland, Ohio. September 1985.
4. **R Zimlichman**, D Zilberman, V Gueta. Hemodynamic effects of nisoldipine in young hypertensives. Presented in the 12th scientific meeting of the international society of hypertension Kyoto, Japan, 1988.
5. **R Zimlichman**, New approach to treatment of hypertension. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.
6. **R Zimlichman**, D Zilberman, V Gueta. Treatment of hypertension with Nisoldipine: Normalization of hemodynamic parameters. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.
7. E Heldman, **R Zimlichman**, M Levin, L Raveh, HB Pollard. Relationship between catecholamine secretion and distinct calcium fluxes in medullary chromaffin cells. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.
8. **R Zimlichman**, S Zimlichman, DS Goldstein, HR Keiser. Angiotensin II regulates catecholamine secretion through a cytosolic calcium dependent mechanism. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.
9. **R Zimlichman**. State of the art lecture- Recent advances in therapy of the hypertensive patient. The 9th European Congress of Anesthesiology, Jerusalem, Israel Oct 2-7, 1994.
10. **R Zimlichman**, J Barg, Z Matas, S Gass, C Shahar, Y Nakash, L Zeidel,

HE Eliahou. Hyperinsulinemia and salt load increase blood pressure in SHR but not in WKY rats, but their effect is not additive.. The Tenth Scientific Meeting of The American Society of Hypertension, New York, 1995.

11. **R. Zimlichman**. Experimental Hyperinsulinemia in rats- state of the art review. 3rd IEN Meeting, Geneva, Switzerland, June 1995.
12. H.E. Eliahou, L. Zeidel, . Gefel, J. Barg, C. Shahar, Y. Nakash, Z. Matas, S. Gass, **R. Zimlichman**. Insulin increases arteriolar wall thickness in SHR and WKY rats independently of blood pressure. Fifth European Meeting on Cardioneurology, Assisi, Italy, 1995.
13. J. Barg J, M.M. Belcheva, **R. Zimlichman**, R. Levy, D. Saya, R.J. McHale, F.E. Johnsonn, C.J. Coscia, Z. Vogel. Opioids inhibit intracellular Ca⁺⁺ mobilization in rat C6 glioma cells. North Falmouth, Massachusetts, USA, 1994.
14. **R. Zimlichman**. Present Drug Therapies- Treatment of Hypertension. 9th European Congress of Anesthesiology, Tel Aviv, 1998.
15. **R. Zimlichman** Hadassah Medical Organization – Hypertension in the Elderly JDC – Brookdale Institute of Gerontology and Human Development, 1998.
16. Losartan or Verapamil in experimental chronic renal failure. H. Eliahou, **R. Zimlichman**, A. Ben-David, T. Chaimi, C. Shahar, Z. Matas- ASN program and Abstracts 32nd Annual Meeting and 1999 Renal Week November 1-8, 1999- Miami Beach, Florida.
17. The History of Hypertension Diagnosis, Treatment and Approach, Israel Society of Internal Medicine Meeting, May 2001.
The 3rd International Symposium on Perioperative Cardiac Care, A Joint Anesthesiology-Cardiology Meeting, Invited Lecture: Update Inhibitors in the Perioperative Period. February, 2001.
19. **R. Zimlichman**. The 1st European Study of arterial compliance and Cardiovascular disease. Interactive Summit on vascular compliance: Focus on identification and management, Nov 16, 2002, Chicago Illinois. Satellite of the American Heart meeting.
20. **R. Zimlichman**. Dyslipidemia and arterial compliance. Interactive Summit on vascular compliance: Focus on identification and management, Nov 16, 2002, Chicago Illinois. Satellite of the American Heart Meeting.
21. **R. Zimlichman** – 18th International Diabetes Federation Congress, August, 2003, Paris, France.
22. **R. Zimlichman** - 5th International Congress on Coronary Artery Disease from Prevention to Intervention – ICCAD – Florence, Italy, October, 2003.
23. **R. Zimlichman** ICCAD 6 – 6th International Congress Coronary Artery Disease from Prevention to Intervention – Istanbul, Turkey, Oct. 29th- Nov. 1st, 2005.
24. 7th International Dead Sea Symposium on Cardiac Arrhythmias and Devices Therapy, Invited Lecture: Hypertension and Cardiac Arrhythmias. Participation in

- 7th International Dead Sea Symposium on Cardiac Arrhythmias and Devices
Therapy, 2004.
25. **R. Zimlichman** – 1st International Congress on “Prediabetes” and the Metabolic
Syndrome – April, 2005, Berlin, Germany.

D2. PAPERS PRESENTED AT SCIENTIFIC MEETINGS

1. **R. Zimlichman**, C. Chaimovitz, J. Kaplanski. Hemodynamics of experimental hypertension in moderate renal failure. Presented in the annual meeting of the Israeli Society of Physiology and Pharmacology, Bar Ilan University, Tel Aviv, 1982.
2. **R. Zimlichman**, J. Kaplanski, G. Genczik, N. Hanuka, C. Chaimovitz. Hemodynamics of experimental liver cirrhosis. Presented in the annual Meeting of the Israeli Society of Physiology and Pharmacology, Weitzman Institute, Rehovot, 1983.
3. **R. Zimlichman**, C. Chaimovitz, J. Chaitchenko. Hemodynamic changes in hypertension of moderate renal failure. Presented in the Biannual Meeting of the Israeli Society of Medicine. Tel Aviv, 1983.
4. **R. Zimlichman**, C. Chaimovitz. Diuretic induced idiopathic edema. Presented in the Biannual Meeting of the Israeli Society of Medicine. Tel Aviv, 1983.
5. **R. Zimlichman**, E. Heldman, HB Pollard, HR Keiser. Cytosolic calcium levels, calcium influx and catecholamine secretion in cultured bovine chromaffin cells. Presented in the Annual Meeting of the American Society for clinical Investigation, Washington D.C. May 1985.
6. **R. Zimlichman**, S. Zimlichman, DS Goldstein, HR Keiser. Lack of effect of ANF on cytosolic calcium levels in platelets of SHR and WKY rats. Presented in the Annual Meeting of the American Federation for Clinical Research, Washington D.C. May 1985.
7. DS Goldstein, **R. Zimlichman**, RW Stull, JC Folio, HR Keiser. Measurement of regional neuronal removal of norepinephrine in man. Presented in the Annual Meeting of the National Council for High Blood Pressure Research. Cleveland, Ohio. September 1985.
8. DS Goldstein, **R. Zimlichman**, RW Stull, HR Keiser, IJ Kopin. Estimation of intrasynaptic norepinephrine concentrations in man. Presented in the 39th Annual fall Conference of the Council for High Blood Pressure Research, Cleveland, Ohio. Sept 1985.
9. J Menczel, **R. Zimlichman**. Effect of Vit. D, PTH, and prostaglandins on cytosolic calcium levels in rat osteosarcoma cells. Presented in the Annual Meeting of the American Society for Bone and Mineral Research. Washington D.C.
10. **R. Zimlichman**. Cytosolic Calcium and Hypertension. Presented in the Israeli Society of Medicine meeting Shefaiim, Nov 1985.
11. **R. Zimlichman**, DS Goldstein, S Zimlichman, RW Stull, HR Keiser. Angiotensin II increases cytosolic calcium and stimulates catecholamine release in adrenomedullary cells. Presented in the 40th Annual fall Conference of the Council for High Blood Pressure Research. Cleveland, Ohio. September 1985.
12. **R. Zimlichman**, S Zimlichman, HR Keiser, DS Goldstein. Lack of Effect of Ouabain On Cytosolic Calcium. Presented in the 2nd International Symposium on Hypertension in the Community. Jerusalem, Israel. Dec 1985.
13. **R. Zimlichman**, DS Goldstein, RD Cannon, HR Keiser. Clinical Evaluation of Impedance Cardiography. Presented in the 2nd International Symposium on Hypertension in the Community. Jerusalem, Israel. Dec. 1985.

14. **R Zimlichman**, DS Goldstein, RW Stull, G E senhofer, G Kelly, HR Keiser. Comparison of norepinephrine and isoproterenol removal in the kanine hindlimb and kidney. Presented in the American Federation for Clinical Research meeting, Washington D.C. May 1986.
15. E Baldi, M Maggi, ML De Feo, C Pupilli, **R Zimlichman**, E Forsberg, M Mannelli Opioid peptides in human adrenal medulla: Their role in modulation of catecholamine secretion. Presented in the International Society of Hypertension meeting, Essen, FRG, September 1986.
16. **R. Zimlichman**, HB Pollard, HR Keiser, E Heldman. Calcium influx but not cytosolic calcium levels regulate catecholamine secretion. Presented in the International Society of Hypertension, Heidelberg, FRG, September 1986.
17. S Shany, E Barnea, I Nathan, **R. Zimlichman**, C Chaimovitz, R Levy. Intercellular free calcium alterations are associated with the effects of 1,25(OH)₂D₃ on leukemic cells. Presented in Cell Calcium Metabolism- VIIth International Washington Spring Symposium, Washington, May 1987.
18. **R Zimlichman**, D Zilberman, V Gueta. Hemodynamic effects of nisoldipine in young hypertensives. Presented in the 12th scientific meeting of the international society of hypertension Kyoto, Japan, 1988.
19. **R.Zimlichman**, DS Goldstein, HR Keiser. Angiotensin II and catecholamine release in cultured adrenomedullary cells. Presented in the 12th world congress of the Israel Medical association, Jerusalem, 1988.
20. **R Zimlichman**, B Gold, L Eidelman, D Zilberman, V Gueta. Evaluation of the acute and long-term hemodynamic effects of convertin in essential hypertension. Presented in the Israel-Germany binational meeting, Eilat, Israel, Jan 1989.
21. IA Ovssyshcher, **R Zimlichman**, A Katz, D Zilberman. Hemodynamic comparison of single chamber versus dual chamber pacing by impedance cardiography. Presented in the Annual Meeting of the Israeli Heart Society. Tel-Aviv, 1989.
22. **R Zimlichman**, D Mossinson, N Cristal, IA Ovssyshcher. Assessment of hemodynamic changes in the early phase of uncomplicated myocardial infarction. Presented in the Annual Meeting of the Israeli Heart Society. Tel Aviv, 1989.
23. **R Zimlichman**, New approach to treatment of hypertension. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.
24. **R Zimlichman**, D Zilberman, V Gueta. Treatment of hypertension with Nisoldipine: Normalization of hemodynamic parameters. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.
25. E Heldman, **R Zimlichman**, M Levin, L Raveh, HB Pollard. Relationship between catecholamine secretion and distinct calcium fluxes in medullary chromaffin cells. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, 1989.
26. **R Zimlichman**, S. Zimlichman, DS Goldstein, HR Keiser. Angiotensin II regulates catecholamine secretion through a cytosolic calcium dependent mechanism. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.
27. **R Zimlichman**, B Gold, L Eidelman, D Zilberman, V Gueta. Evaluation of the acute and long-term hemodynamic effects of convertin in essential hypertension. Calcium in Cardiovascular disease, an International Symposium, Eilat Israel, April 1989.

28. **R Zimlichman**, L Eidelman, B Gold. Evaluation of the acute and long term hemodynamic effects of enalapril in essential hypertension. Fourth European Meeting on Hypertension, Milan 1989.
 29. **R Zimlichman**. Lowering blood pressure is not enough- a new approach to treatment of hypertension: Normalization of hemodynamic parameters. Fourth European Meeting on Hypertension, Milan 1989.

 30. **R Zimlichman**. Modern approach to treatment of hypertension. The Israeli Society of Hypertension, Medax 1989.
-
31. **R Zimlichman**. State of the art lecture- Recent advances in therapy of the hypertensive patient. The 9th European Congress of Anesthesiology, Jerusalem, Israel Oct 2-7, 1994.
 32. IA Ovsyshcher, A Katz, **R Zimlichman**, V Gueta. Thoracic impedance cardiography as a noninvasive method for continuous assessment of cardiac patients. Presented in The Israeli Society of Cardiology April, 1994.
 33. **R Zimlichman**, H Eliahou, S Gass, Z Vogel, J Barg. Insulin induces hypertrophy of cardiomyocytes in culture. Fourth European Congress of Cell Biology, Jerusalem, 1994, Israel.
 34. J Barg, M Belcheva, **R Zimlichman**, R Levy, RJ Sayal, RJ McHale, FE Johnson, CJ Coscia, Z Vogel. Opioids inhibit intracellular Ca⁺⁺ mobilization in rat C6 glioma cells. INRC meeting Cape Cod, Massachusetts, 1994, USA.
 35. **R Zimlichman**, N Gasper, L Eidelman, B Gold. Prolonged treatment with Captopril attenuates vascular hyperreactivity in patients with essential hypertension. The Seventh Scientific Meeting of the American Society of Hypertension, New York, 1992.
 36. A Blau, S Tal, **R Zimlichman**, N Kogan, T Benaim, L Shulman, A Knecht, S Gavendo, HE Eliahou. Plasma insulin and blood pressure are reduced independently of weight loss in overweight hypertensive patients. Proc of the 14th Scientific Meeting of the International Society of Hypertension, p 186, 1992.
 37. Z Vogel, J Barg, HE Eliahou, S Gass, C Ela, Y Eilam, **R Zimlichman**. Opioid agonist inhibits endothelin mediated CA⁺⁺ mobilization in rat cardiomyocytes. Tenth Meeting of the European Society for Neurochemistry, Jerusalem, Israel, 1994.
 38. **R Zimlichman**, HE Eliahou, S Gass, Z Vogel, J Barg. Insulin induces hypertrophy of cardiomyocytes and proliferation of noncardiomyocytes in culture. Tenth Meeting of the European Society for Neurochemistry, Jerusalem, Israel, 1994.
 39. **R Zimlichman**, J Barg, S Gass, Z Matas, Y Nakash, L Zeidel, C Shahar, HE Eliahou. Insulin induces blood pressure elevation in SHR but not WKY rats. The Annual Meeting of Israeli Society of Nephrology, Herzlia, May 1994.
 40. A Debby, **R Zimlichman**, HE Eliahou, CH Zakut. Prediction of IUGR in early pregnancy of hypertensive women. The Annual Meeting of Israeli Society of Nephrology, Herzlia, May 1994.
 41. HE Eliahou, A Blau, S Tal, **R Zimlichman**. Reduction in blood pressure and in fasting blood insulin after body weight reduction in overweight hypertensive

patients do not correlate. Meeting of the Israeli Diabetes association, Tel Aviv, Israel, Jan 18 1994.

42. A Tanay, D Gefel, R Tuvar, Y Shoenfeld, **R Zimlichman**. Generalized non-dependent edema in patients with SLE who lack renal, hepatic and cardiac pathology. Fourth International Conference on SLE, Tel Aviv, Israel, 1995.
43. **R Zimlichman**, N Zamir, D Gefel, A Omer, HE Eliahou, B Rosen, S Gass, J Barg. Endothelin and Nifedipine modulate cardiomyocyte contraction and ANF production.

44. **R Zimlichman**, J Barg, S Gass, Z Matas, Y Nakash, L Zeidel, C Shahar, HE Eliahou. Insulin induces blood pressure elevation in SHR but not WKY rats. The 48th Council for High Blood Pressure Research, September 1994, Chicago Ill.
45. **R Zimlichman**, HE Eliahou, S Gass, Z Vogel, J Barg. Insulin induces hypertrophy of cardiomyocytes and proliferation of non-cardiomyocytes in culture. The 48th Council for High Blood Pressure Research, September 1994, Chicago Ill.
46. **R Zimlichman**, E Cohen-Melamed, Z Madar. Acarbose Improves Insulin Sensitivity and Reduces Blood Pressure in Sucrose Induced Hypertension in Rats. The Tenth Scientific Meeting of The American Society of Hypertension, New York, 1995.
47. **R Zimlichman**, L Zeidel, J Barg, D Gefel, Z Matas, S Gass, C Shahar, HE Eliahou. Hyperinsulinemia Induces Vascular Wall Thickness in SHR and WKY Rats independently of Blood Pressure Change. The Tenth Scientific Meeting of The American Society of Hypertension, New York, 1995.
48. **R Zimlichman**, HE Eliahou, S Gass, Z Vogel, D Gefel, J Barg. Insulin Induces Hypertrophy of Cardiomyocytes and proliferation of non-cardiomyocytes in culture. The Tenth Scientific Meeting of The American Society of Hypertension, New York, 1995.
49. **R Zimlichman**, N Zamir, HE Eliahou, D Gefel, O Porat, B Rosen, S Gass, J Barg. Endothelin and Nifedipine modulate differently myocyte contraction and ANP secretion in cultured atrial myocytes of SHR and WKY rats. The Tenth Scientific Meeting of The American Society of Hypertension, New York, 1995.
50. **R Zimlichman**, J Barg, Z Matas, S Gass, C Shahar, Y Nakash, L Zeidel, HE Eliahou. Hyperinsulinemia and salt load increase blood pressure in SHR but not in WKY rats, but their effect is not additive.. The Tenth Scientific Meeting of The American Society of Hypertension, New York, 1995.
51. HE Eliahou, **R Zimlichman**, J Barg, D Gefel, S Gass, Z Matas, Y Nakash, L Zeidel, C Shahar. Hyperinsulinemia increases blood pressure in SHR rats where genetic predisposition exists but not in WKY rats. The Tenth Scientific Meeting of The American Society of Hypertension, New York, 1995.
52. **R. Zimlichman**. Experimental Hyperinsulinemia in rats- state of the art review. 3rd IEN Meeting, Geneve, Swizerland, June 1995.
53. **R Zimlichman**, J Barg, Z Matas, S Gass, C Shahar, Y Nakash, HE Eliahou ,

- Insulin and salt are not additive in increasing blood pressure in rats, Israeli Society of Nephrology and Hypertension, Annual Conference, Zichron Yaacov, June 1995.
54. **R. Zimlichman**, HE Eliahou, L Zeidel, J Barg, Z Matas, S Gass, C Shahaar, Insulin induces hypertrophy of media of myocardial arterioles in rats. Israeli Society of Nephrology and Hypertension, Annual Conference, Zichron Yaacov, June 1995.
 55. **R. Zimlichman** Hadassah Medical Organization - Hypertension in the Elderly JDC- Brookdale Institute of Gerontology and Human Development_ Vol. pp. 193-198, 1998.
 56. Losartan or Verapamil in experimental chronic renal failure: H. Eliahou, **R. Zimlichman**, A. Ben-David, T. Chaimi, C. Shahaar, Z. Matas- ASN program and Abstracts 32nd Annual Meeting and 1999 Renal Week November 1-8, 1999- Miami Beach, Florida.
 57. The History of Hypertension Diagnosis, Treatment and Approach, Israel Society on Internal Medicine Meeting, May, 2001.
 58. The 3rd International Symposium on Perioperative Cardiac Care, A Joint Anesthesiology-Cardiology Meeting, Invited Lecture: Update Inhibitors in the Perioperative Period. February, 2001.
 59. **R. Zimlichman** The 1st European Study of arterial compliance and Cardiovascular disease. Interactive Summit on vascular compliance: Focus on identification and management., Nov. 2002.
 60. **R. Zimlichman** Dyslipidemia and arterial compliance. Interactive Summit on vascular compliance: Focus on identification and management, Nov. 16, 2002, Chicago, Illinois. Satellite of the American Heart Meeting.
 61. **R. Zimlichman** 18th International Diabetes Federation Congress, 24-29 August, 2003, Paris, France.
 62. **R. Zimlichman** 5th International congress on coronary Artery Disease from prevention to Intervention – ICCAD – Florence, Italy, 19-22nd October, 2003.
 63. **R. Zimlichman**, 7th International Dead Sea Symposium on Cardiac Arrhythmias and Devices Therapy, Invited lecture: Hypertension and Cardiac Arrhythmias.
 64. **R. Zimlichman** 1st International Congress on “Prediabetes” and the Metabolic syndrome – 16th April, 2005, Berlin, Germany.
 65. The Seven European Sites study of Arterial Elasticity- Using blood pressure waveform analysis- Reliability, Repeatability and establishment of normal values for healthy European population. Reuven Zimlichman, Presented at the American Society of Hypertension Meeting, May 2003.
 66. Effects of moderate smoking on arterial elasticity in healthy European population- The Seven European Sites Study of Arterial Elasticity. Reuven Zimlichman, Presented at the American Society of Hypertension Meeting, May 2003.
 67. Effects of modest wine/beer drinking on arterial elasticity in healthy European population- The seven European sites study (SESS). Reuven Zimlichman, Presented at the American Society of Hypertension Meeting, May, 2003.

68. **R. Zimlichman** The Journal of Coronary Artery Disease Vol. 5 No.1,205 (760) – Arterial Stiffness in Health and Disease. The 5th International Congress on Coronary Artery Disease – from Prevention to Intervention ICCAD – Florence, Italy, October, 2003
69. Effects of family history on Arterial Elasticity in healthy European population- The seven European sites study of arterial elasticity (AE).
70. **Reuven Zimlichman**, Presented at the American Society of Hypertension Meeting, May, 2003.
71. Reduction of hyperinsulinemia with rosiglitazone reduces Sigur hyperinsulinemia, improves small vessel elasticity and metabolic parameters in patients with niddm. M. Shargorodsky, Presented at American Society of Hypertension Meeting, May 2004. **R. Zimlichman**.
72. Treatment with rosiglitazone induces significant decrease in blood pressure in hypertensive and normotensive patients with NIDDM. **R. Zimlichman**. Presented at American Society of Hypertension Meeting, May 2004
73. Prolonged treatment of hypertensive patients with HCTZ improves arterial elasticity but not if they have NIDDM or IFG- in these it aggravates metabolic parameters. **R. Zimlichman**. Presented at American Society of Hypertension Meeting, May 2004

74. Healthy morbidly obese subjects without risk factors have normal arterial elasticity which does not improve after significant weight loss, while morbidly obese patients with multiple risk factors have decreased arterial elasticity and improve after significant weight loss- evaluation of arterial elasticity, inflammatory markers and humoral factors before and after laparoscopic introduction of adjustable lap band. **R. Zimlichman** Presented at American Society of Hypertension Meeting, May 2004
75. Arterial stiffness in health and disease: are there healthy vessels in healthy population?. **Reuven Zimlichman**, Presented at the European Society of Hypertension, Paris, June 2004.
76. Morbidly obese patients without cv risk factors have normal arterial compliance with no improvement after weight loss however if multiple risk factors are present they have decreased arterial elasticity and improve after significant weight loss: evaluation of arterial elasticity, inflammatory markers and humoral factors before and after surgical intervention for morbid obesity (lap band). **R. Zimlichman**. Presented at the European Society of Hypertension, Paris, June 2004.
77. **R. Zimlichman** Prolonged treatment with HCTZ in patients with hypertension and NIDDM lowers blood pressure but aggravates metabolic parameters and does not improve arterial compliance. Artery 4, Association for Research Into Arterial Structure and Physiology, London Oct 2004.
78. **R. Zimlichman**. Morbid obesity without Cardiovascular risk factors is associated with normal arterial compliance. When multiple risk factors are present -weight loss improves arterial compliance and metabolic parameters. Artery 4,

- Association for Research Into Arterial Structure and Physiology, London Oct 2004.
79. **R. Zimlichman** Arterial stiffness in health and disease. Artery 4, Association for Research Into Arterial Structure and Physiology, London Oct 2004
 80. **R. Zimlichman** H. Gutman, M. Shragorodsky, R. Brendeis, D. Gavish, 20th Annual Scientific Meeting Long Term Oral Supplementation of L-Arginine, San Francisco, Calif., USA – 14 – 18 May 2005.
 81. **R. Zimlichman** H. Gutman, M. Shragorodsky, R. Brendeis, D. Gavish, 20th Annual Scientific Meeting Long Term Oral Supplementation of L-Arginine, San Francisco, Calif., USA – 14 – 18 May 2005.
 82. H. Gutman, M. Shargorodsky, R. Brendeis, D. Gavish, **R. Zimlichman** – American Journal of Hypertension Vol. 18, No. 5, Part 2 of 2 pp.13A 14A, 20A, 154A(P-12) San Francisco, May, 2005, Long Term Oral supplementation of L-Arginine.
 83. Y. Goldberg, M. Shargorodsky, D. Gavish, **R. Zimlichman** – The Journal of Hypertension Vol. 23 (suppl.2) (P2.240) pp.S214, 216,218, 229, 231 Weight Loss and Mild Physical Activity improve small and large arterial elasticity and lower Blood pressure in obese patients. 15th European Meeting on Hypertension, Milan, Italy, June 2005.
 84. **R. Zimlichman** Y. Goldberg, M. Shargorodsky, D. Gavish, 15th European meeting on Hypertension, Milan, Italy, 17-21 June 2006.
 85. Y. Goldberg, M. Shargorodsky, D. Gavish, **R. Zimlichman** - Weight Loss and Mild Physical Activity improve small and large arterial elasticity and lower blood pressure in Obese Patients. American Society Hypertension Meeting New York, 2006. European Hypertension Meeting, Madrid 2006.

 86. M. Shargorodsky, Y. Goldberg, D. Gavish, **R. Zimlichman** – Weight Loss and Mild Physical activity decrease the levels of inflammatory markers in Obese with Metabolich Syndrome. American Society Hypertension Meeting, New York 2006, European Hypertension meeting, Madrid 2006.
 87. M. Shargorodsky, H. Gutman, R. Brendeis, D. Gavish, **R. Zimlichman** – The Link between Nitric oxide System and Aldosterone: Long term oral supplementation of L-Arginine improves Arterial Elasticity and Hemodynamic variables. American Society Hypertension Meeting, New York 2006, European Hypertension Meeting, Madrid 2006.
 88. K. Confino, M. Shargorodsky, D. Gavish, Z. Matas, M. Fuchs, M. Boaz, **R. Zimlichman**. Effect of Long Term Treatment with Spironolactone on Arterial Elasticity in Patients with Cardiovascular Risk Factors, and/or Atherosclerosis. 17th European Society Meeting on Hypertension, Milan June 15-19, 2007.

89. O. Debby, **M. Shargorodsky**, D. Gavish, Z. Matas, M. Fuchs, M. Boaz, R. Zimlichman. The Effect of Prolonged Treatment with Antioxidants: Vitamin C, E, Coenzyme Q10 and Selenium on Arterial Elasticity, Humoral, Metabolic and inflammatory Factors in Patients with CVRF or Atherosclerosis. 17th European Society Meeting on Hypertension, Milan June 15-19, 2007.
90. M. Cimand, **M. Shargorodsky**, D. Gavish, Z. Matas, M. Fuchs, M. Boaz, R. Zimlichman. The Effect of Homocysteine lowering therapy with folic acid, Vitamin B6 and B12 on arterial elasticity, metabolic, Humoral and inflammatory Parameters in patients with CVRF and or Atherosclerosis. 17th European Society Meeting on Hypertension, Milan June 15-19, 2007.
91. R. Zimlichman. Invited lecture.
1st World Congress of Controversies in Cardiovascular Diseases: Diagnosis, Treatment and Intervention (C-CARE). July 3-6, Berlin Germany.
Blood Pressure- How low? With what?.

Listing stopped because of numerous presentations.

D-3. ABSTRACTS

1. **R. Zimlichman**, J. Kaplanski, G. Genczik, N. Hanuka.
Evaluation of hemodynamic changes and renal perfusion in experimental liver cirrhosis in rats. *Isr J Med Sci*, Vol, p. 461, 1984
- R. Zimlichman**, C. Chaimovitz, Y. Chaitcheno. Hemodynamic basis of hypertension in rats with renal failure. *Isr J Med Sci*, Vol. 19, p. 301, 1984.
3. **R. Zimlichman**, S. Zimlichman, D.S. Goldstein, H.R. Keiser.
Intracellular calcium levels and calcium kinetics in platelets from SHR and WKY rats. *Clin Res*, Vol. 33, p. 555A, 1985.
4. **R. Zimlichman**, E. Heldman, H.B. Pollard, H.R. Keiser.
Relationship between intracellular calcium levels and catecholamine release. *Clin Res*, Vol. 33, p. 371A, 1985.
5. **R. Zimlichman**, S. Zimlichman, D.S. Goldstein, H.R. Keiser.
Lack of effect of Atrial Natriuretic Factor on platelet intracellular calcium levels in platelets of SHR and WKY rats. *Clin Res*, Vol. 33, p. 371A, 1985.
6. D.S. Goldstein, **R. Zimlichman**, R.W. Stull, H.R. Keiser, I.J. Kopin.
Estimation of intrasynaptic norepinephrine concentrations in man. *Hypertension*, Vol. 7, p. 842, 1985.
7. J. Menczel, **R. Zimlichman**, Effect of Vit. D, PTH, and prostaglandins on cytosolic calcium levels in rat osteosarcoma cells. *J Metab Bone Res*.
8. **R. Zimlichman**, D.S. Goldstein, R.W. Stull, G. Eisenhofer, G. Kelly, H.R. Keiser.
Comparison of norepinephrine and isoproterenol removal in the kanine hindlimb and kidney. *Clin Res*, Vol. 34, p. 409A, 1986.
9. E. Baldi, M. Maggi, M.L. De Feo, C. Pupilli, **R. Zimlichman**, E. Forsberg, M. Mannelli. Opioid peptides in human adrenal medulla: Their role in modulation of catecholamine secretion. Proceedings of the satellite meeting of ISH, Essen FRG, Springer Verlag.
- R. Zimlichman**, H.B. Pollard, H.R. Keiser, E. Heldman. Calcium influx but not cytosolic calcium levels regulate catecholamine secretion. *J Hypertension*,.
11. **R. Zimlichman**, D.S. Goldstein, S. Zimlichman, R.W. Stull, H.R. Keiser.
Angiotensin II increases cytosolic calcium and stimulates catecholamine release in adrenomedullary cells. *Hypertension*,.
12. **R. Zimlichman**, D.S. Goldstein, R.W. Stull, G. Eisenhofer, G. Kelly, H.R. Keiser.
Comparison of norepinephrine and isoproterenol removal in the canine hindlimb and kidney. *Clin Res*.
13. **R. Zimlichman**, D. Zilberman, V. Gueta. Hemodynamic effects of nisoldipine in young hypertensives. *J Hypertension*,.
14. I.Y. Ovsyshcher, **R. Zimlichman**, A. Katz, D. Zilberman.
Hemodynamic comparison of single chamber versus dual chamber pacing by impedance cardiography. *Isr J Med Sci*, Vol. 25, p. 468, 1989.
15. **R. Zimlichman**, D. Mossinson, N. Cristal, I.Y. Ovsyshcher.
Assessment of hemodynamic changes in the early phase of uncomplicated myocardial infarction. *Isr J Med Sci*, Vol. 25, p. 479, 1989.
16. **R. Zimlichman**, L. Eidelman, B. Gold. Evaluation of the acute and long term hemodynamic effects of enalapril in essential hypertension.

Proceedings of the Fourth European Meeting on Hypertension, Milan 1989.

17. **R. Zimlichman**. Lowering blood pressure is not enough- a new approach to treatment of hypertension: Normalization of hemodynamic parameters. Fourth European Meeting on Hypertension, Milan 1989.
18. **R. Zimlichman**. Modern approach to treatment of hypertension. Proceedings of The Israeli Society of Hypertension Medax 1989.
19. **R. Zimlichman**, N Gasper, L Eidelman, B Gold. Prolonged treatment with Captopril attenuates vascular hyperreactivity in patients with essential hypertension. The Seventh Scientific Meeting of the American Society of Hypertension, New York, 1992. Am J Hypertens 1992;5:(pt 20) 12A.
20. **R. Zimlichman**, E Cohen-Melamed, Z Madar. Acarbose Improves Insulin Sensitivity and Reduces Blood Pressure in Sucrose Induced Hypertension in Rats. The Tenth Scientific Meeting of The American Society of Hypertension, New York, Am J Hypertension, 8:52A, 1995.
21. **R. Zimlichman**, L Zeidel, J Barg, D Gefel, Z Matas, S Gass, C Shahaar, HE Eliahou. Hyperinsulinemia Induces Vascular Wall Thickness in SHR and WKY Rats independently of Blood Pressure Change. The Tenth Scientific Meeting of The American Society of Hypertension, New York, Am J Hypertension, 8:52A, 1995.
22. **R. Zimlichman**, HE Eliahou, S Gass, Z Vogel, D Gefel, J Barg. Insulin Induces Hypertrophy of Cardiomyocytes and proliferation of non-cardiomyocytes in culture. The Tenth Scientific Meeting of The American Society of Hypertension, New York, Am J Hypertension, 8:52A 1995.
23. **R. Zimlichman**, N Zamir, HE Eliahou, D Gefel, O Porat, B Rosen, S Gass, J Barg. Endothelin and Nifedipine modulate differently myocyte contraction and ANP secretion in cultured atrial myocytes of SHR and WKY rats. The Tenth Scientific Meeting of The American Society of Hypertension, New York, Am J Hypertension, 8:164A 1995.
24. **R. Zimlichman**, J Barg, Z Matas, S Gass, C Shahaar, Y Nakash, L Zeidel, HE Eliahou. Hyperinsulinemia and salt load increase blood pressure in SHR but not in WKY rats, but their effect is not additive.. The Tenth Scientific Meeting of The American Society of Hypertension, New York, Am J Hypertension, 8:42A 1995.
25. HE Eliahou, **R. Zimlichman**, J Barg, D Gefel, S Gass, Z Matas, Y Nakash, L Zeidel, C Shahaar. Hyperinsulinemia increases blood pressure in SHR rats where genetic predisposition exists but not in WKY rats. The Tenth Scientific Meeting of The American Society of Hypertension, New York, Am J Hypertension, 8:51A 1995.

G. OTHER PUBLICATIONS - LETTERS TO THE EDITOR

1. I.A. Ovsyshcher, **R. Zimlichman**. Infective endocarditis in hypertrophic cardiomyopathy secondary to amiodarone treatment (letter). Chest, Vol. 83, p. 833, 1983.
2. I.A. Ovsyshcher, **R. Zimlichman**. Polymorphous ventricular tachycardia (letter). Am. J. Cardiol, Vol. 51, pp. 1571-1572, 1983
3. C. Chaimovitz, **R. Zimlichman**, M. Zlotnik. Continuous ambulatory peritoneal dialysis (letter). Isr J Med Sci, Vol. 19, pp. 575-576, 1983.
4. **R. Zimlichman**. Cytosolic calcium (letter). N Eng J Med, Vol. 313, p. 520, 1986.
5. E. Eisenberg, **R. Zimlichman**, P. Lavie. Plasma norepinephrine levels in patients with sleep apnea syndrome (letter). N Eng J Med Vol 322, pp. 932-933, 1990.
6. **R. Zimlichman**, S. Krauss, E. Paran. Muscle cramps and beta antagonists with intrinsic sympathomimetic activity (letter). Arch Int Med, Vol 151, pp. 1021, 1991.
7. **R. Zimlichman**. The Seventh Scientific Meeting of the American Society of Hypertension- What's New. Harefuah (Medicine Isr), 124:243, 1993 (letter).
8. **R. Zimlichman**. The 14th Scientific meeting of the International Society of Hypertension- What's New. Melbourne, Australia, Harefuah (Medicine Isr), 1994 (letter).
9. **R. Zimlichman**. Nisoldipine and treatment of hypertension. Isr J Med Sci 30:, 1994 (letter).